Open in Screener

INCY

Incyte Corp

Jul 25 • 04:00PM ET

70.20

Dollar change -0.29
Percentage change -0.41	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN GILD IONS BMY MRK JNJ AMGN PFE LLY

| Held by: VTI VOO VB VBK RSP SPY IVV XBI USMV IBB

Index	S&P 500	P/E	217.20	EPS (ttm)	0.32	Insider Own	1.39%	Shs Outstand	193.78M	Perf Week	3.45%
Market Cap	13.59B	Forward P/E	10.37	EPS next Y	6.77	Insider Trans	-3.08%	Shs Float	190.87M	Perf Month	3.92%
Enterprise Value	11.22B	PEG	2.22	EPS next Q	1.42	Inst Own	100.49%	Short Float	3.73%	Perf Quarter	19.04%
Income	21.27M	P/S	3.08	EPS this Y	431.19%	Inst Trans	5.67%	Short Ratio	3.85	Perf Half Y	-3.21%
Sales	4.41B	P/B	3.71	EPS next Y	18.45%	ROA	0.33%	Short Interest	7.12M	Perf YTD	1.64%
Book/sh	18.93	P/C	5.64	EPS next 5Y	98.01%	ROE	0.47%	52W High	83.95 -16.38%	Perf Year	6.69%
Cash/sh	12.44	P/FCF	44.89	EPS past 3/5Y	-66.90% -40.36%	ROIC	0.57%	52W Low	53.56 31.07%	Perf 3Y	-14.90%
Dividend Est.	-	EV/EBITDA	37.90	Sales past 3/5Y	12.41% 14.46%	Gross Margin	91.16%	Volatility	1.96% 2.41%	Perf 5Y	-36.00%
Dividend TTM	-	EV/Sales	2.54	EPS Y/Y TTM	-88.78%	Oper. Margin	4.68%	ATR (14)	1.69	Perf 10Y	-40.02%
Dividend Ex-Date	-	Quick Ratio	2.00	Sales Y/Y TTM	17.13%	Profit Margin	0.48%	RSI (14)	55.91	Recom	2.24
Dividend Gr. 3/5Y	- -	Current Ratio	2.04	EPS Q/Q	6.97%	SMA20	2.01%	Beta	0.71	Target Price	76.15
Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	19.53%	SMA50	3.83%	Rel Volume	0.78	Prev Close	70.49
Employees	2617	LT Debt/Eq	0.01	Earnings	Jul 29 BMO	SMA200	2.92%	Avg Volume	1.85M	Price	70.20
IPO	Nov 04, 1993	Option/Short	Yes / Yes	EPS/Sales Surpr.	18.55% 6.88%	Trades		Volume	1,434,800	Change	-0.41%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-16-25	Upgrade	Stifel	Hold → Buy	$107
Mar-18-25	Downgrade	William Blair	Outperform → Mkt Perform
Mar-18-25	Downgrade	Guggenheim	Buy → Neutral
Dec-17-24	Initiated	UBS	Neutral	$77
Oct-29-24	Upgrade	BofA Securities	Neutral → Buy	$68 → $90
Oct-01-24	Initiated	Wolfe Research	Outperform	$84
Sep-18-24	Downgrade	Truist	Buy → Hold	$83 → $74
Jul-02-24	Downgrade	BMO Capital Markets	Market Perform → Underperform	$52 → $48
May-23-24	Initiated	Deutsche Bank	Hold	$55
Apr-23-24	Initiated	Cantor Fitzgerald	Neutral
Feb-23-24	Initiated	Jefferies	Buy	$81
Feb-14-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-13-23	Upgrade	Leerink Partners	Market Perform → Outperform	$78
Dec-04-23	Upgrade	Guggenheim	Neutral → Buy	$86
Nov-21-23	Downgrade	Goldman	Buy → Neutral	$98 → $65
Jul-25-23	Initiated	Citigroup	Buy	$82
May-04-23	Downgrade	BofA Securities	Buy → Neutral	$84
Apr-10-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$81 → $79
Mar-24-23	Upgrade	SVB Securities	Underperform → Market Perform	$61
Jan-31-23	Initiated	Piper Sandler	Overweight	$100

Show Previous Ratings

Jul-24-25 11:47PM	Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects (Insider Monkey)
05:02PM	Incyte To Present Initial Data for its TGFR2PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025 (Business Wire)
11:42AM	Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards? (Zacks)
10:00AM	Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-23-25 10:53AM	Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth? (Zacks)
10:00AM	Loading…
Jul-22-25 10:00AM	Incyte (INCY) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-17-25 09:40AM	Is BrightSpring Health Services, Inc. (BTSG) Outperforming Other Medical Stocks This Year? (Zacks)
Jul-16-25 11:40AM	INCY or TECH: Which Is the Better Value Stock Right Now? (Zacks)
Jul-10-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
08:00AM	Incyte to Report Second Quarter Financial Results (Business Wire)
Jul-09-25 10:09AM	William Blair Maintains 'Hold' Rating on Incyte Corporation (INCY), Citing Future Revenue Uncertainties (Insider Monkey)
Jul-02-25 04:30PM	Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-01-25 09:33AM	Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock? (Zacks)
Jun-30-25 09:15AM	Jim Cramer Highlights That Incyte's New CEO is an "Industry Veteran" (Insider Monkey)
Jun-27-25 01:14PM	Incyte Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
12:21PM	Loading…
12:21PM	Shell denies deal talks with BP, Micron reports Q3 beat: Morning Buzz (TipRanks)
Jun-26-25 04:45PM	Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role? (Investor's Business Daily)
09:16AM	Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes (Investor's Business Daily)
07:30AM	Incyte Appoints Bill Meury Chief Executive Officer; Herv Hoppenot to Retire (Business Wire)
Jun-24-25 03:05AM	How Is Incytes Stock Performance Compared to Other Biotech Stocks? (Barchart)
Jun-23-25 09:53AM	FDA Extends INCY's Application for Opzelura Label Expansion (Zacks)
12:19AM	5 Revealing Analyst Questions From Incyte's Q1 Earnings Call (StockStory)
Jun-20-25 04:30PM	Update on FDA Review of Ruxolitinib Cream (Opzelura) for Children Ages 2-11 with Atopic Dermatitis (Business Wire)
Jun-19-25 11:11AM	Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma (Zacks)
Jun-18-25 03:39PM	Incyte Announces FDA Approval of Monjuvi (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma (Business Wire)
Jun-17-25 12:08PM	Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics (Zacks)
09:35AM	Cisco upgraded, CoreWeave downgraded: Wall Streets top analyst calls (TipRanks)
Jun-16-25 08:27AM	QGEN Stock Rises in After Market Following Partnership With Incyte (Zacks) +5.12%
07:06AM	Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms (Medical Device Network)
Jun-15-25 05:49AM	Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches (Insider Monkey)
04:00AM	Loading…
04:00AM	QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) (Business Wire)
03:15AM	Positive Late-Breaking Data for Incytes First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025 (Business Wire)
Jun-13-25 12:05PM	Specialised Therapeutics announces expanded partnership with Incyte (TipRanks)
Jun-12-25 06:45PM	Phase 3 Data for Incytes Retifanlimab (Zynyz) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet (Business Wire)
Jun-06-25 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:08PM	Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector? (MarketWatch)
11:31AM	Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-05-25 11:30AM	Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report? (Zacks)
Jun-03-25 10:30AM	Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025 (Business Wire)
May-29-25 07:58PM	Analyst Report: Incyte Corporation (Morningstar Research)
11:30AM	Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report? (Zacks)
May-27-25 08:00AM	Incyte to Present at Upcoming Investor Conference (Business Wire)
May-22-25 12:02AM	3 Reasons INCY is Risky and 1 Stock to Buy Instead (StockStory)
May-20-25 05:06PM	S&P 500 Gains and Losses Today: FICO Stock Falls as Federal Housing Official Questions Pricing (Investopedia)
May-19-25 09:26AM	FDA approves Incytes retifanlimab combo for SCAC treatment (Pharmaceutical Technology)
May-16-25 10:51AM	Incyte Gets FDA Approval for Zynyz in New Cancer Indication (Zacks)
May-15-25 02:30PM	Incyte Announces FDA Approval of Zynyz (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States (Business Wire)
May-14-25 07:49AM	Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying (Insider Monkey)
May-07-25 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-06-25 01:13PM	Q1 2025 Syndax Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-05-25 05:06AM	I Scanned The S&P 500 For GARP Stocks; Here's What I Found (Seeking Alpha)
May-01-25 08:00AM	Incyte to Present at Upcoming Investor Conference (Business Wire)
Apr-30-25 03:06AM	Incyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... (GuruFocus.com)
Apr-29-25 03:20PM	Analyst Report: Incyte Corporation (Morningstar Research)
12:53PM	Incyte Corporation (INCY) Q1 2025 Earnings Call Transcript (Seeking Alpha)
11:04AM	INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales (Zacks)
09:30AM	Here's What Key Metrics Tell Us About Incyte (INCY) Q1 Earnings (Zacks)
09:03AM	3 Value Stocks Facing Headwinds (StockStory)
08:15AM	Incyte (INCY) Q1 Earnings and Revenues Top Estimates (Zacks)
07:29AM	Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers (StockStory)
07:12AM	Incyte: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs (Business Wire)
Apr-28-25 03:04AM	Incyte (INCY) Q1 Earnings Report Preview: What To Look For (StockStory)
Apr-25-25 08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
08:00AM	Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025 (Business Wire)
Apr-24-25 10:01AM	Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-23-25 11:03AM	Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (Business Wire)
07:50AM	Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know (Zacks)
Apr-22-25 10:01AM	Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-10-25 08:00AM	Incyte to Report First Quarter Financial Results (Business Wire) -6.27%
Apr-08-25 09:15AM	AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis (Zacks) -5.51%
Apr-07-25 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:08AM	Syndax Pharmaceuticals: Down But Not Out (Seeking Alpha)
05:01AM	Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY) (StockStory)
Apr-04-25 08:50AM	Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings (Zacks)
Apr-01-25 05:05AM	3 Reasons INCY is Risky and 1 Stock to Buy Instead (StockStory)
Mar-26-25 07:30AM	Knight Therapeutics Announces Launch of Minjuvi (tafasitamab) in Mexico (GlobeNewswire)
Mar-25-25 06:20AM	Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now? (Zacks)
Mar-24-25 06:20AM	Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? (Zacks)
Mar-22-25 06:46AM	What Moved Markets This Week (SeekingAlpha)
Mar-21-25 11:56AM	Why Incyte Stock Was Tanking This Week (Motley Fool)
09:01AM	1 Healthcare Stock on Our Watchlist and 2 to Brush Off (StockStory)
04:46AM	The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics (Zacks)
02:30AM	Incyte Had a Bad Week. Investors Are Used to It. (Barrons.com)
Mar-20-25 01:03PM	3 Promising Biotechs Trading Substantially Under Consensus Analyst Firm Price Targets (SeekingAlpha)
12:45PM	Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More (Zacks)
Mar-19-25 08:06AM	Incyte price target lowered to $72 from $74 at Truist (TipRanks)
Mar-18-25 07:01PM	Analyst Report: Incyte Corporation (Morningstar Research)
08:05AM	Stoke CEO exits; Medicare drug price talks advance (BioPharma Dive)
05:32AM	Incyte Corporation (INCY): Among the Best Biotech Stocks to Buy According to Billionaires (Insider Monkey)
Mar-17-25 04:52PM	Incyte stock dives after drug trial disappoints investors (Yahoo Finance Video) -8.62%
04:32PM	S&P 500 Gains and Losses Today: Index Ticks Higher Ahead of This Week's Fed Decision (Investopedia)
04:11PM	Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive' (Investor's Business Daily)
02:09PM	Oil pressures, Robinhood, Incyte: Market Minute (Yahoo Finance Video)
01:52PM	Why Incyte (INCY) Stock Is Nosediving (StockStory)
01:11PM	Incyte stock hit 11% despite paediatric dermatology trials hitting target (Clinical Trials Arena)
12:00PM	Top Stock Movers Now: Intel, Netflix, Incyte, and More (Investopedia)
12:00PM	Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results (Investopedia)
11:21AM	Incyte Is Todays Worst S&P 500 Stock. Heres Why. (Barrons.com)
11:20AM	Nvidia, Netflix, Berkshire Hathaway, Baidu, Incyte, NCL, Affirm: Stocks to watch today (Quartz)

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stein Steven H	EVP & Chief Medical Officer	Jul 21 '25	Sale	67.94	3,706	251,786	102,886	Jul 23 03:56 PM
STEVEN STEIN	Officer	Jul 21 '25	Proposed Sale	67.94	3,706	251,786		Jul 21 04:01 PM
Flannelly Barry P	EVP & General Manager US	Jul 16 '25	Sale	68.36	1,340	91,602	35,149	Jul 17 04:06 PM
Iyengar Vijay K	EVP, GMAPPS	Jul 16 '25	Sale	68.36	983	67,198	40,540	Jul 17 04:05 PM
Denton Sheila A.	EVP & General Counsel	Jul 15 '25	Option Exercise	64.25	3,330	213,952	29,834	Jul 17 04:04 PM
Denton Sheila A.	EVP & General Counsel	Jul 15 '25	Sale	69.86	3,330	232,634	26,504	Jul 17 04:04 PM
Denton Sheila A.	EVP & General Counsel	Jul 16 '25	Sale	68.36	785	53,663	33,200	Jul 17 04:04 PM
VIJAY IYENGAR	Officer	Jul 16 '25	Proposed Sale	68.36	983	67,198		Jul 16 04:07 PM
BARRY FLANNELLY	Officer	Jul 16 '25	Proposed Sale	68.36	1,340	91,602		Jul 16 04:06 PM
Stein Steven H	EVP & Chief Medical Officer	Jul 14 '25	Sale	68.47	14,952	1,023,763	97,466	Jul 16 04:05 PM
SHEILA DENTON	Officer	Jul 16 '25	Proposed Sale	68.36	785	53,663		Jul 16 04:02 PM
Iyengar Vijay K	EVP, GMAPPS	Jul 15 '25	Sale	69.86	1,177	82,225	35,929	Jul 16 04:02 PM
Flannelly Barry P	EVP & General Manager US	Jul 15 '25	Sale	69.86	1,192	83,273	37,630	Jul 16 04:02 PM
BARRY FLANNELLY	Officer	Jul 15 '25	Proposed Sale	69.86	1,192	83,273		Jul 15 04:41 PM
SHEILA DENTON	Officer	Jul 15 '25	Proposed Sale	69.86	3,330	232,634		Jul 15 04:37 PM
VIJAY IYENGAR	Officer	Jul 15 '25	Proposed Sale	69.86	1,177	82,225		Jul 15 04:20 PM
STEVEN STEIN	Officer	Jul 14 '25	Proposed Sale	68.47	14,952	1,023,714		Jul 14 04:03 PM
Flannelly Barry P	EVP & General Manager US	Jul 03 '25	Sale	68.15	10,903	743,039	39,744	Jul 07 04:46 PM
Denton Sheila A.	EVP & General Counsel	Jul 02 '25	Option Exercise	58.06	599	34,778	27,103	Jul 07 04:44 PM
Denton Sheila A.	EVP & General Counsel	Jul 02 '25	Sale	68.61	599	41,097	26,504	Jul 07 04:44 PM
Iyengar Vijay K	EVP, GMAPPS	Jul 03 '25	Sale	68.15	8,617	587,275	37,701	Jul 07 04:43 PM
BARRY FLANNELLY	Officer	Jul 03 '25	Proposed Sale	68.15	10,903	743,048		Jul 03 03:10 PM
VIJAY IYENGAR	Officer	Jul 03 '25	Proposed Sale	68.15	8,617	587,272		Jul 03 02:46 PM
SHEILA DENTON	Officer	Jul 02 '25	Proposed Sale	68.61	599	41,097		Jul 02 04:27 PM
Denton Sheila A.	EVP & General Counsel	Jun 03 '25	Option Exercise	58.06	1,795	104,218	28,299	Jun 05 04:04 PM
Denton Sheila A.	EVP & General Counsel	Jun 03 '25	Sale	68.00	1,795	122,060	26,504	Jun 05 04:04 PM
SHEILA DENTON	Officer	Jun 03 '25	Proposed Sale	68.00	1,795	122,060		Jun 03 04:06 PM
Tray Thomas	Principal Accounting Officer	May 30 '25	Sale	65.71	963	63,279	22,654	Jun 03 04:00 PM
Tray Thomas	Principal Accounting Officer	Jun 02 '25	Sale	64.88	651	42,237	22,003	Jun 03 04:00 PM
THOMAS R TRAY	Officer	Jun 02 '25	Proposed Sale	64.88	651	42,237		Jun 02 04:26 PM
THOMAS R TRAY	Officer	May 30 '25	Proposed Sale	65.71	963	63,279		May 30 04:03 PM
Flannelly Barry P	EVP & General Manager US	Mar 14 '25	Sale	67.69	19,807	1,340,656	33,567	Mar 18 04:01 PM
BARRY FLANNELLY	Officer	Mar 14 '25	Proposed Sale	67.69	19,807	1,340,728		Mar 14 04:11 PM
Denton Sheila A.	EVP & General Counsel	Mar 04 '25	Option Exercise	58.06	599	34,778	26,447	Mar 06 04:56 PM
Denton Sheila A.	EVP & General Counsel	Mar 04 '25	Sale	69.99	599	41,924	25,848	Mar 06 04:56 PM
SHEILA DENTON	Officer	Mar 04 '25	Proposed Sale	69.99	599	41,924		Mar 04 05:12 PM
Denton Sheila A.	EVP & General Counsel	Feb 26 '25	Option Exercise	58.06	9,574	555,866	39,917	Feb 28 06:34 PM
Denton Sheila A.	EVP & General Counsel	Feb 26 '25	Sale	74.07	14,069	1,042,136	25,848	Feb 28 06:34 PM
SHEILA DENTON	Officer	Feb 26 '25	Proposed Sale	74.07	14,069	1,042,138		Feb 26 04:04 PM
Stein Steven H	EVP & Chief Medical Officer	Jan 21 '25	Sale	72.69	12,352	897,867	66,967	Jan 22 04:05 PM
STEVEN STEIN	Officer	Jan 21 '25	Proposed Sale	72.69	12,352	897,906		Jan 21 04:03 PM
Tray Thomas	Principal Accounting Officer	Dec 13 '24	Sale	70.64	650	45,916	23,962	Dec 17 12:37 PM
Tray Thomas	Principal Accounting Officer	Dec 16 '24	Sale	69.31	650	45,052	23,312	Dec 17 12:37 PM
THOMAS R TRAY	Officer	Dec 16 '24	Proposed Sale	69.31	650	45,052		Dec 16 04:04 PM
Iyengar Vijay K	EVP, GMAPPS	Nov 29 '24	Sale	75.38	6,043	455,544	30,658	Dec 03 12:52 PM
VIJAY IYENGAR	Officer	Nov 29 '24	Proposed Sale	75.39	6,043	455,555		Nov 29 01:28 PM
Flannelly Barry P	EVP & General Manager US	Nov 06 '24	Option Exercise	70.03	3,680	257,719	61,722	Nov 08 12:48 PM
Flannelly Barry P	EVP & General Manager US	Nov 06 '24	Sale	79.68	3,680	293,210	58,042	Nov 08 12:48 PM
BARRY FLANNELLY	Officer	Nov 06 '24	Proposed Sale	79.68	3,680	293,210		Nov 06 04:15 PM
Tray Thomas	Principal Accounting Officer	Sep 12 '24	Sale	62.94	572	36,002	24,825	Sep 16 01:25 PM
Tray Thomas	Principal Accounting Officer	Sep 13 '24	Sale	63.37	382	24,207	24,443	Sep 16 01:25 PM
Dickinson Jonathan Elliott	EVP, General Manager, Europe	Sep 12 '24	Sale	62.36	8,450	526,948	36,390	Sep 16 01:24 PM
THOMAS R TRAY	Officer	Sep 13 '24	Proposed Sale	63.37	382	24,207		Sep 13 04:06 PM
JONATHAN ELLIOTT DICKINSON	Officer	Sep 12 '24	Proposed Sale	62.36	8,450	526,930		Sep 12 04:17 PM
Stein Steven H	EVP & Chief Medical Officer	Aug 12 '24	Sale	60.63	11,608	703,793	90,011	Aug 14 03:37 PM
STEVEN STEIN	Officer	Aug 12 '24	Proposed Sale	60.63	11,608	703,771		Aug 12 04:39 PM

Open in Screener

NOTV

Inotiv Inc

Jul 25 • 04:00PM ET

2.22

Dollar change -0.14
Percentage change -5.93	%

Healthcare • Diagnostics & Research • USA • NASD

Peers: CRL ICON IQV MEDP CROX CERS BMRN CTLT EXEL NBIX

| Held by: VTI VXF PRFZ IWC AVSC

Index	-	P/E	-	EPS (ttm)	-3.18	Insider Own	13.81%	Shs Outstand	34.35M	Perf Week	26.50%
Market Cap	76.26M	Forward P/E	-	EPS next Y	-1.25	Insider Trans	-2.47%	Shs Float	29.61M	Perf Month	22.65%
Enterprise Value	508.55M	PEG	-	EPS next Q	-0.39	Inst Own	23.24%	Short Float	8.26%	Perf Quarter	15.62%
Income	-87.47M	P/S	0.16	EPS this Y	56.95%	Inst Trans	-7.30%	Short Ratio	4.17	Perf Half Y	-50.56%
Sales	480.40M	P/B	0.48	EPS next Y	30.71%	ROA	-11.06%	Short Interest	2.45M	Perf YTD	-46.38%
Book/sh	4.59	P/C	3.95	EPS next 5Y	77.23%	ROE	-47.95%	52W High	6.48 -65.74%	Perf Year	8.82%
Cash/sh	0.56	P/FCF	-	EPS past 3/5Y	- -122.90%	ROIC	-14.76%	52W Low	1.15 93.04%	Perf 3Y	-86.11%
Dividend Est.	-	EV/EBITDA	77.64	Sales past 3/5Y	76.27% 62.27%	Gross Margin	10.06%	Volatility	13.45% 9.36%	Perf 5Y	-54.32%
Dividend TTM	-	EV/Sales	1.06	EPS Y/Y TTM	-15.29%	Oper. Margin	-10.90%	ATR (14)	0.21	Perf 10Y	8.82%
Dividend Ex-Date	-	Quick Ratio	0.93	Sales Y/Y TTM	-13.09%	Profit Margin	-18.21%	RSI (14)	55.36	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	1.50	EPS Q/Q	76.51%	SMA20	11.68%	Beta	4.03	Target Price	5.50
Payout	-	Debt/Eq	2.86	Sales Q/Q	4.44%	SMA50	0.66%	Rel Volume	0.56	Prev Close	2.36
Employees	2075	LT Debt/Eq	2.76	Earnings	Aug 06 AMC	SMA200	-22.93%	Avg Volume	586.07K	Price	2.22
IPO	Nov 25, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	30.71% 0.29%	Trades		Volume	327,474	Change	-5.93%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-24	Downgrade	Jefferies	Buy → Hold	$11.50 → $3.75
Feb-09-24	Upgrade	Jefferies	Hold → Buy	$3 → $11.50
Jul-20-23	Initiated	Wells Fargo	Overweight	$9
Jan-19-23	Downgrade	Jefferies	Buy → Hold	$10 → $8
Jan-11-23	Upgrade	Lake Street	Hold → Buy	$4 → $10
Nov-18-22	Downgrade	Lake Street	Buy → Hold	$60 → $7
Oct-04-22	Initiated	Jefferies	Buy	$27
Jan-31-22	Initiated	Lake Street	Buy	$60
Sep-20-21	Initiated	Craig Hallum	Buy	$45

Jul-23-25 07:00AM	Inotiv, Inc. to Report Fiscal 2025 Third Quarter Financial Results and Host Conference Call on Wednesday, August 6, 2025 (GlobeNewswire) +7.14%
May-22-25 04:05PM	Inotiv, Inc. to Present at Jefferies Global Healthcare Conference 2025 (GlobeNewswire)
May-08-25 03:28AM	Inotiv Inc (NOTV) Q2 2025 Earnings Call Highlights: Revenue Growth and Strategic Optimizations ... (GuruFocus.com) +10.20%
12:05AM	Inotiv outlines revised RMS site optimization plan with $6.5M investment and $6M-$7M annual savings projection (Seeking Alpha)
12:03AM	Inotiv, Inc. (NOTV) Q2 2025 Earnings Call Transcript (Seeking Alpha)
06:45PM	Loading…
May-07-25 06:45PM	Inotiv, Inc. (NOTV) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +14.20%
04:05PM	Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update (GlobeNewswire)
May-06-25 08:45AM	Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates (Zacks) -13.73%
May-01-25 10:01AM	Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-30-25 10:01AM	Inotiv, Inc. (NOTV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-23-25 04:05PM	Inotiv, Inc. to Report Fiscal 2025 Second Quarter Financial Results and Host Conference Call on Wednesday, May 7, 2025 (GlobeNewswire) +7.27% +8.47%
Feb-06-25 02:14AM	Inotiv Inc (NOTV) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth ... (GuruFocus.com) -6.22%
Feb-05-25 04:05PM	Inotiv Reports First Quarter Financial Results for Fiscal 2025 and Provides Business Update (GlobeNewswire) -7.01%
Jan-22-25 04:05PM	Inotiv, Inc. to Report Fiscal 2025 First Quarter Financial Results and Host Conference Call on Wednesday, February 5, 2025 (GlobeNewswire)
Dec-30-24 04:05PM	Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $3.6 Million (GlobeNewswire) -11.06%
04:05PM	Loading…
Dec-23-24 04:05PM	Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million (GlobeNewswire) +14.97%
Dec-18-24 08:00AM	Inotiv, Inc. Announces Pricing of Public Offering of 6,000,000 Common Shares (GlobeNewswire) -28.83%
Dec-17-24 04:03PM	Inotiv, Inc. Launches Proposed Public Offering of Common Shares (GlobeNewswire)
Dec-04-24 02:00AM	Inotiv Inc (NOTV) Q4 2024 Earnings Call Highlights: Revenue Growth Amid Operational Challenges (GuruFocus.com) -6.21%
Dec-03-24 04:05PM	Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2024 and Provides Business Update (GlobeNewswire) +7.44%
Dec-02-24 07:02AM	Inotiv Inc (NOTV) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +6.56%
Nov-21-24 08:30AM	Inotiv Ranked Number 138 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500 (GlobeNewswire) +6.23%
Nov-20-24 04:05PM	Inotiv, Inc. to Report Fiscal 2024 Fourth Quarter and Full Year Results and Host Conference Call on Tuesday, December 3, 2024 (GlobeNewswire) +15.05%
Nov-07-24 08:00AM	Inotiv, Inc. to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences (GlobeNewswire) +8.23%
Oct-09-24 05:54PM	Inotiv Inc (NOTV) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines and Strategic ... (GuruFocus.com)
Sep-16-24 08:00AM	Inotiv, Inc. Amends Its Credit Agreement and Secures Additional Liquidity (GlobeNewswire) +18.97%
Aug-28-24 04:05PM	Inotiv to Participate in the 8th Annual Lake Street Best Ideas Growth Conference (GlobeNewswire) +9.29%
Aug-08-24 06:15PM	Inotiv, Inc. (NOTV) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +5.66%
04:05PM	Inotiv Reports Third Quarter Financial Results for Fiscal 2024 and Provides Business Update (GlobeNewswire)
Jul-25-24 08:00AM	Inotiv, Inc. to Report Fiscal 2024 Third Quarter Financial Results and Host Conference Call on Thursday, August 8, 2024 (GlobeNewswire)
06:50AM	Loading…
Jul-09-24 06:50AM	3 Breakout Stocks to Buy Before They Make Headlines (InvestorPlace)
Jul-01-24 10:20AM	3 Undervalued Stocks Primed for a 2X Return (InvestorPlace)
Jun-10-24 07:30AM	Inotiv, Inc. Provides Business Updates (GlobeNewswire) +6.43%
Jun-03-24 02:49PM	Company that bred beagles for research pleads guilty to neglect, ordered to pay record $35M fine (Associated Press Finance) +16.04%
01:24PM	Inotiv Reaches Agreement to Resolve Previously-Announced Investigation into Shuttered Cumberland Facility (GlobeNewswire)
May-23-24 04:15PM	Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences (GlobeNewswire)
May-15-24 09:54PM	NOTV Stock Earnings: Inotiv Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace) +5.66%
04:05PM	Inotiv Reports Second Quarter Financial Results for Fiscal 2024 and Provides Business Update (GlobeNewswire)
May-14-24 08:19AM	Why Is Inotiv (NOTV) Stock Down 35% Today? (InvestorPlace) -49.16%
07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Wednesday, May 15, 2024 (GlobeNewswire)
May-10-24 05:20AM	Inotiv Delays Release of Fiscal Q2 Results (MT Newswires) -9.62%
May-09-24 06:56PM	Inotiv, Inc. Reschedules its Fiscal 2024 Second Quarter Results (GlobeNewswire) -12.42%
Apr-29-24 04:05PM	Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Friday, May 10, 2024 (GlobeNewswire) -7.65%
Apr-03-24 08:50AM	Inotiv (NOTV) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Apr-02-24 08:50AM	Why Fast-paced Mover Inotiv (NOTV) Is a Great Choice for Value Investors (Zacks)
Mar-25-24 09:40AM	Is Inotiv (NOTV) a Great Value Stock Right Now? (Zacks)
Mar-18-24 08:50AM	Here's Why Momentum in Inotiv, Inc. (NOTV) Should Keep going (Zacks)
Mar-12-24 04:42PM	Rocket Stocks: 3 Picks That Could Skyrocket Your Portfolio by 2025 (InvestorPlace) +9.96%
Mar-07-24 04:20PM	3 Stocks That Could Fast-Track Your Millionaire Status (InvestorPlace) +6.54%
12:00PM	Inotiv, Inc. (NOTV) is a Great Momentum Stock: Should You Buy? (Zacks)
08:50AM	Despite Fast-paced Momentum, Inotiv, Inc. (NOTV) Is Still a Bargain Stock (Zacks)
Mar-01-24 09:40AM	Should Value Investors Buy Inotiv (NOTV) Stock? (Zacks) +7.25%
Feb-29-24 08:50AM	Here's What Could Help Inotiv, Inc. (NOTV) Maintain Its Recent Price Strength (Zacks) +13.57%
Feb-27-24 01:34PM	3 Overlooked Stocks with Potential for 500% Growth by 2025 (InvestorPlace)
Feb-20-24 07:38AM	Millionaire-Makers: 3 Game-Changing Stocks Ready for Historic Gains (InvestorPlace) +6.52%
Feb-19-24 08:50AM	Inotiv, Inc. (NOTV) Is Attractively Priced Despite Fast-paced Momentum (Zacks)
Feb-14-24 09:40AM	Are Investors Undervaluing Inotiv (NOTV) Right Now? (Zacks) +10.23%
Feb-09-24 08:25AM	Inotiv, Inc. (NASDAQ:NOTV) Q1 2024 Earnings Call Transcript (Insider Monkey) +15.35%
Feb-08-24 09:55AM	Inotiv Inc (NOTV) Reports Revenue Growth and Reduced Net Loss in Q1 FY 2024 (GuruFocus.com) +16.85%
08:54AM	Q1 2024 Inotiv Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-07-24 06:10PM	Inotiv, Inc. (NOTV) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update (GlobeNewswire)
Jan-29-24 04:05PM	Inotiv, Inc. to Report Fiscal 2024 First Quarter Financial Results and Host Conference Call on Wednesday, February 7, 2024 (GlobeNewswire) -5.22%
Jan-27-24 09:00AM	Big Pharmas great lab monkey shortage: A crackdown on smuggling is causing chaos in Americas vital drug development pipeline (Fortune)
Dec-16-23 03:01PM	Insider Buying: COO John Beattie Acquires 47,966 Shares of Inotiv Inc (NOTV) (GuruFocus.com)
Dec-15-23 08:50AM	Inotiv, Inc. (NOTV) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks)
Dec-14-23 08:14AM	Inotiv, Inc. (NASDAQ:NOTV) Q4 2023 Earnings Call Transcript (Insider Monkey) +12.32%
Dec-12-23 07:45AM	Q4 2023 Inotiv Inc Earnings Call (Thomson Reuters StreetEvents) -15.84%
Dec-11-23 09:54PM	NOTV Stock Earnings: Inotiv Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -10.36%
04:05PM	Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2023 and Provides Business Update (GlobeNewswire)
Dec-06-23 04:30PM	Inotiv, Inc. Announces Plan to Insource North American Transportation Operations (GlobeNewswire) +14.55%
Nov-27-23 04:05PM	Inotiv, Inc. to Report Fiscal 2023 Fourth Quarter and Full Year Results and Host Conference Call on Monday, December 11, 2023 (GlobeNewswire) -13.73% +6.12%
Nov-13-23 04:05PM	Inotiv Provides Business Updates and Upcoming Investor Conferences Update (GlobeNewswire) +16.48%
Nov-08-23 07:30AM	Inotiv Ranked Number 127 Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 (GlobeNewswire)
Nov-01-23 08:00AM	Inotiv, Inc. to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-16-23 08:00AM	Inotiv, Inc. Announces Changes to its Board Composition (GlobeNewswire) +21.95%
Aug-29-23 06:47PM	Inotiv Announces the Sale of its Israeli Businesses to Harlan Holdings Ltd. (GlobeNewswire)
Aug-24-23 04:05PM	Inotiv, Inc. to Participate in Upcoming September 2023 Investor Conferences (GlobeNewswire) -6.55%
Aug-15-23 03:31PM	Inotiv Faces SEC Probe on Imports of Monkeys From Asia (The Wall Street Journal) -6.86%
Aug-10-23 06:15PM	Inotiv, Inc. (NOTV) Q3 Earnings Miss Estimates (Zacks) -35.63%
04:08PM	Inotiv Reports Third Quarter Financial Results for Fiscal 2023 and Provides Business Update (GlobeNewswire)
Jul-24-23 04:35PM	Inotiv, Inc. to Report Fiscal 2023 Third Quarter Financial Results and Host Conference Call on Thursday, August 10, 2023 (GlobeNewswire) -5.76%
Jul-20-23 08:24PM	Strength Seen in Inotiv, Inc. (NOTV): Can Its 34.5% Jump Turn into More Strength? (Zacks) +34.52%
Jun-30-23 08:44AM	Are Options Traders Betting on a Big Move in Inotiv (NOTV) Stock? (Zacks)
Jun-05-23 09:55AM	Does Inotiv, Inc. (NOTV) Have the Potential to Rally 185.14% as Wall Street Analysts Expect? (Zacks)
May-30-23 08:50AM	Here Is Why Bargain Hunters Would Love Fast-paced Mover Inotiv, Inc. (NOTV) (Zacks)
May-25-23 08:33AM	Inotiv, Inc. to Present at Jefferies 2023 Healthcare Conference (GlobeNewswire)
May-19-23 08:33AM	Inotiv, Inc. to Participate in May Investor Conferences (GlobeNewswire)
May-18-23 09:55AM	Wall Street Analysts Predict a 168.98% Upside in Inotiv, Inc. (NOTV): Here's What You Should Know (Zacks)
May-13-23 08:15AM	Inotiv Second Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-11-23 05:55PM	Inotiv, Inc. (NOTV) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -11.13%
04:05PM	Inotiv, Inc. Announces Second Quarter Fiscal 2023 Financial Results (GlobeNewswire)
May-08-23 08:18AM	Inotiv's (NASDAQ:NOTV) investors will be pleased with their splendid 235% return over the last five years (Simply Wall St.) +8.05%
06:27AM	4D Molecular Therapeutics, Inc. (FDMT) Surges 5.4%: Is This an Indication of Further Gains? (Zacks)
May-04-23 08:33AM	Inotiv, Inc. Expands Safety Pharmacology Offering to Include Cardiopulmonary Telemetry (GlobeNewswire)
Apr-26-23 08:33AM	Inotiv, Inc. to Report Fiscal 2023 Second Quarter Financial Results and Host Conference Call on Thursday, May 11, 2023 (GlobeNewswire)
Apr-11-23 09:00AM	Inotiv Applauded by Frost & Sullivan as Key Competitor in the Bio-analytical Testing Services Market (PR Newswire) +7.23%
07:27AM	Great news for Inotiv, Inc. (NASDAQ:NOTV): Insiders acquired stock in large numbers last year (Simply Wall St.)
Mar-24-23 08:38AM	Implied Volatility Surging for Inotiv (NOTV) Stock Options (Zacks)

Inotiv, Inc. is a pharmaceutical development company, which engages in the provision of nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to academia and government clients. It operates under the Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments. The DSA segment focuses on drug discovery and development services. The RMS segment includes commercial production and selling research models, diets, bedding, and bioproducts. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Neff R Matthew	Director	Jul 01 '25	Sale	1.81	2,000	3,621	151,102	Jul 03 04:30 PM
Neff R Matthew	Director	Jun 02 '25	Sale	2.62	2,000	5,246	153,102	Jun 04 04:05 PM
Neff R Matthew	Director	Jun 02 '25	Proposed Sale	2.60	6,000	15,600		Jun 02 10:26 AM
Coelho Mary Theresa	Director	Apr 01 '25	Sale	2.35	5,500	12,916	74,303	Apr 02 04:32 PM
Coelho Mary Theresa	Director	Apr 01 '25	Proposed Sale	2.83	5,500	15,565		Apr 01 06:33 PM
Freeman Jeffrey Brennan	VP-Finance & Corp. Controller	Feb 18 '25	Sale	4.04	1,339	5,416	27,478	Feb 20 04:34 PM
Taylor Beth	Chief Financial Officer	Feb 18 '25	Sale	4.01	4,370	17,507	108,368	Feb 20 04:33 PM
Sagartz John E	Chief Strategy Officer	Feb 18 '25	Sale	3.94	2,113	8,316	707,816	Feb 20 04:33 PM
Leasure Robert Jr.	President and CEO	Feb 18 '25	Sale	3.82	73,617	281,136	956,592	Feb 20 04:32 PM
Leasure Robert Jr.	President and CEO	Jan 31 '25	Sale	4.15	22,700	94,298	1,030,209	Feb 04 04:15 PM
Taylor Beth	Chief Financial Officer	Jan 31 '25	Sale	4.46	2,054	9,171	112,738	Feb 04 04:14 PM
Sagartz John E	Chief Strategy Officer	Jan 31 '25	Sale	4.48	2,118	9,479	709,929	Feb 04 04:13 PM
Krupp Jeffrey Arthur	Chief Human Resources Officer	Jan 31 '25	Sale	4.48	2,036	9,123	29,029	Feb 04 04:12 PM
Krupp Jeffrey Arthur	Chief Human Resources Officer	Feb 03 '25	Sale	4.18	472	1,973	28,557	Feb 04 04:12 PM
Landman David	Director	Dec 19 '24	Buy	4.25	23,529	99,998	176,851	Dec 23 09:47 PM
Beattie John Gregory	Chief Operating Officer	Dec 10 '24	Buy	4.75	30,000	142,500	161,761	Dec 12 06:46 PM
Brown Nigel	Director	Dec 10 '24	Buy	4.26	7,500	31,950	65,537	Dec 10 04:13 PM
Harrington Michael J	Director	Dec 06 '24	Buy	3.98	10,000	39,822	37,500	Dec 10 08:34 AM
Landman David	Director	Dec 06 '24	Buy	4.14	100,000	414,000	153,322	Dec 10 08:31 AM

Dollar change -0.17
Percentage change -0.10	%

CRL Charles River Laboratories International Inc daily Stock Chart

Peers: IQV LDOS MEDP CVS PFE ILMN BMY LH MRK

| Held by: VTI VOO VB RSP VBR SPY IVV XLV IBB IWR

Index	S&P 500	P/E	-	EPS (ttm)	-0.65	Insider Own	1.12%	Shs Outstand	49.12M	Perf Week	14.53%
Market Cap	8.69B	Forward P/E	17.13	EPS next Y	10.33	Insider Trans	0.44%	Shs Float	48.56M	Perf Month	17.79%
Enterprise Value	11.50B	PEG	-	EPS next Q	2.50	Inst Own	109.02%	Short Float	4.77%	Perf Quarter	52.84%
Income	-31.56M	P/S	2.16	EPS this Y	-6.49%	Inst Trans	0.32%	Short Ratio	2.22	Perf Half Y	6.03%
Sales	4.02B	P/B	2.72	EPS next Y	7.05%	ROA	-0.40%	Short Interest	2.32M	Perf YTD	-4.15%
Book/sh	65.04	P/C	37.74	EPS next 5Y	2.95%	ROE	-0.92%	52W High	254.15 -30.38%	Perf Year	-19.68%
Cash/sh	4.69	P/FCF	15.43	EPS past 3/5Y	-70.29% -47.65%	ROIC	-0.51%	52W Low	91.86 92.61%	Perf 3Y	-23.15%
Dividend Est.	-	EV/EBITDA	12.61	Sales past 3/5Y	4.59% 9.09%	Gross Margin	30.43%	Volatility	5.04% 3.75%	Perf 5Y	-10.61%
Dividend TTM	-	EV/Sales	2.86	EPS Y/Y TTM	-107.31%	Oper. Margin	12.80%	ATR (14)	6.85	Perf 10Y	135.25%
Dividend Ex-Date	-	Quick Ratio	1.16	Sales Y/Y TTM	-2.16%	Profit Margin	-0.78%	RSI (14)	71.32	Recom	2.44
Dividend Gr. 3/5Y	- -	Current Ratio	1.43	EPS Q/Q	-64.42%	SMA20	11.32%	Beta	1.49	Target Price	165.08
Payout	0.00%	Debt/Eq	0.94	Sales Q/Q	-2.71%	SMA50	18.30%	Rel Volume	0.71	Prev Close	177.10
Employees	20100	LT Debt/Eq	0.93	Earnings	Aug 06 BMO	SMA200	8.00%	Avg Volume	1.04M	Price	176.93
IPO	Jun 23, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.73% 4.48%	Trades		Volume	740,418	Change	-0.10%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-09-25	Upgrade	Citigroup	Neutral → Buy	$200
May-23-25	Upgrade	Redburn Atlantic	Neutral → Buy	$182
May-14-25	Upgrade	TD Cowen	Hold → Buy	$179
May-08-25	Upgrade	Evercore ISI	In-line → Outperform	$170
Mar-21-25	Downgrade	Goldman	Buy → Neutral	$190 → $170
Mar-04-25	Upgrade	Citigroup	Sell → Neutral	$155 → $175
Mar-03-25	Upgrade	Redburn Atlantic	Sell → Neutral	$188
Jan-22-25	Downgrade	William Blair	Outperform → Mkt Perform
Jan-17-25	Downgrade	UBS	Buy → Neutral	$250 → $185
Nov-18-24	Downgrade	CLSA	Hold → Underperform	$164
Nov-07-24	Upgrade	CLSA	Underperform → Hold	$205
Oct-23-24	Initiated	CLSA	Underperform	$167
Oct-14-24	Initiated	Redburn Atlantic	Sell
Oct-07-24	Downgrade	Evercore ISI	Outperform → In-line	$225 → $190
Oct-02-24	Downgrade	BofA Securities	Buy → Neutral	$250 → $215
Oct-01-24	Downgrade	Citigroup	Neutral → Sell	$215 → $175
Aug-08-24	Downgrade	Robert W. Baird	Outperform → Neutral	$239 → $191
Aug-08-24	Downgrade	JP Morgan	Overweight → Neutral	$270 → $205
Jun-28-24	Downgrade	Argus	Buy → Hold
Jun-07-24	Initiated	Mizuho	Neutral	$235

Show Previous Ratings

Jul-24-25 10:53AM	Stock Market Today: S&P 500, Nasdaq Touch Records; Rail Merger Talks; West Pharma in Focus (TheStreet) +5.45%
10:53AM	Stock Market Today: Investors Await After-Hours Results from Intel, Newmont, Deckers Brands (TheStreet)
Jul-22-25 12:10PM	Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report? (Zacks) +9.06%
11:56AM	Why Are Charles River Laboratories (CRL) Shares Soaring Today (StockStory)
08:00AM	Charles River Joins Ellys Team to Drive Rare Disease Gene Therapy Development (Business Wire)
08:09AM	Loading…
Jul-18-25 08:09AM	Here's What to Expect From Charles River Laboratories' Next Earnings Report (Barchart)
Jul-16-25 08:19AM	Is it Prudent to Retain Charles River Stock in Your Portfolio Now? (Zacks)
Jul-15-25 01:56PM	Simulations Plus Sees Weaker Demand Persist, Outlook Softens (Benzinga)
09:51AM	Charles River Laboratories International (CRL) is Expected to Gain as Industry Growth Resumes (Insider Monkey)
08:00AM	Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call (Business Wire)
Jul-08-25 08:11AM	Myrtelle Launches Manufacturing of First-in-Class Gene Therapy for Canavan Disease in Strategic Alliance with Charles River and Viralgen (PR Newswire)
Jul-04-25 01:31AM	5 Revealing Analyst Questions From Charles River Laboratories's Q1 Earnings Call (StockStory)
Jun-25-25 11:34AM	Is Charles River Laboratories Stock Underperforming the S&P 500? (Barchart)
Jun-18-25 12:02AM	3 Reasons to Sell CRL and 1 Stock to Buy Instead (StockStory)
Jun-16-25 08:00AM	Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment (Business Wire)
05:28AM	Loading…
Jun-11-25 05:28AM	CRL Q1 Earnings Call: Regulatory Changes and Market Stabilization Shape Outlook (StockStory)
Jun-10-25 03:48PM	Megacap stocks aren't all up in 2025. But this chart shows they've trounced the S&P 500's smallest equities. (MarketWatch)
Jun-06-25 11:31AM	Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report? (Zacks)
Jun-02-25 08:12AM	Charles River Stock May Gain From Extended CHDI Research Deal on HD (Zacks)
08:00AM	Charles River Laboratories to Present at William Blair and Jefferies Conferences (Business Wire)
May-30-25 12:46AM	Charles River Laboratories International, Inc. (CRL): A Bull Case Theory (Insider Monkey)
May-28-25 08:00AM	Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntingtons Disease Research (Business Wire)
May-24-25 03:55AM	Redburn Upgrades Charles River Laboratories (CRL) to Buy, Cuts PT (Insider Monkey)
May-20-25 08:53AM	Should You Continue to Hold Charles River Stock in Your Portfolio? (Zacks)
May-19-25 11:34PM	Drug Development Inputs & Services Stocks Q1 Results: Benchmarking Charles River Laboratories (NYSE:CRL) (StockStory)
May-13-25 09:16AM	Understanding Charles River (CRL) Reliance on International Revenue (Zacks)
08:00AM	Charles River Laboratories to Present at Bank of America Health Care Conference (Business Wire)
May-09-25 07:00AM	Eli Lilly extends Purdue alliance; EMA investigates Valneva shot (BioPharma Dive)
May-08-25 03:18AM	Charles River Laboratories International Inc (CRL) Q1 2025 Earnings Call Highlights: Navigating ... (GuruFocus.com)
May-07-25 09:34PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research) +18.68%
05:19PM	Loading…
05:19PM	S&P 500 Gains & Losses Today: Stocks Gain in Volatile Session as Markets React to Fed Meeting, Trump Trade Comments (Investopedia)
04:22PM	Charles River to initiate a review amid Elliott stake - Is a sale next? (Investing.com)
02:47PM	Charles river raises 2025 guidance with focus on NAMs and cost optimization (Seeking Alpha)
02:46PM	Charles River Laboratories International, Inc. (CRL) Q1 2025 Earnings Call Transcript (Seeking Alpha)
12:17PM	Charles River Stock Is Having Its Best Day in 13 Years. A Board Shake-Up and Business Review Will Help. (Barrons.com)
11:51AM	Top Stock Moves Now: Charles River Labs, Disney, Supermicro, and More (Investopedia)
10:23AM	Charles River Labs Stock Soars as Firm Shakes Up Board, Launches Review (Investopedia)
09:51AM	Charles River announces strategic review including 'examination of various alternatives' (Seeking Alpha)
09:35AM	CRL Q1 Earnings & Revenues Beat Estimates, Stock Rises, '25 View Up (Zacks)
09:30AM	Compared to Estimates, Charles River (CRL) Q1 Earnings: A Look at Key Metrics (Zacks)
09:04AM	Charles River surges after Q1 beat, guidance raise (Seeking Alpha)
08:15AM	Charles River Laboratories (CRL) Beats Q1 Earnings and Revenue Estimates (Zacks)
07:13AM	Charles River: Q1 Earnings Snapshot (Associated Press Finance)
07:01AM	Charles River Laboratories Announces First-Quarter 2025 Results (Business Wire)
07:00AM	Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value (Business Wire)
06:08AM	Charles River to add new directors, review business in agreement with Elliott (Reuters)
May-05-25 12:50PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research)
May-01-25 10:01AM	Progyny (PGNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
09:15AM	ClearBridge All Cap Growth Portfolios Q1 2025 Commentary (Seeking Alpha)
Apr-30-25 07:39PM	Charles River Laboratories International, Inc. (CRL): Among the Worst Performing Stocks in S&P 500 So Far in 2025 (Insider Monkey)
11:45AM	The Davenport Insider Buying Fund Q1 2025 Commentary (Seeking Alpha)
10:01AM	Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-29-25 08:00AM	Charles River Announces Inaugural Advanced Therapy Incubator Program Cohort (Business Wire)
Apr-28-25 09:12AM	Here's How Charles River is Placed Just Ahead of Q1 Earnings (Zacks)
Apr-22-25 10:01AM	Upslope Capital Management Sold Charles River (CRL) Due to Thesis Break (Insider Monkey)
08:00AM	Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development (Business Wire)
Apr-17-25 11:01PM	Charles River Laboratories International, Inc. (CRL): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025 (Insider Monkey)
Apr-16-25 07:55AM	The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid? (MarketBeat)
Apr-15-25 04:30PM	Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call (Business Wire)
10:35AM	Upslope Capital's Q1 2025 Investor Letter (Seeking Alpha)
08:26AM	Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength? (Zacks)
Apr-12-25 08:15AM	Charles River Gets Hit By The FDA, Too Early To Bet On A Comeback (Seeking Alpha)
07:50AM	What Moved Markets This Week (Seeking Alpha)
Apr-11-25 02:36PM	Charles River Faces Significant Regulatory And Macro Pressures (Seeking Alpha)
05:46AM	Why Charles River Laboratories International, Inc. (CRL) Went Down On Thursday? (Insider Monkey)
Apr-10-25 08:43PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research) -28.13%
12:10PM	Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:05AM	Bausch + Lomb (BLCO) Moves 13.9% Higher: Will This Strength Last? (Zacks)
Apr-03-25 07:44PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research) -5.56%
Mar-31-25 09:20AM	Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate (Zacks)
Mar-25-25 08:00AM	Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica, an AI-Powered Drug Discovery Platform (Business Wire)
Mar-24-25 12:34PM	Why Charles River Laboratories International, Inc. (CRL) is Among the Best Diagnostics Stocks to Invest in Right Now (InsiderMonkey)
Mar-21-25 11:30AM	Charles River (CRL) Up 1.9% Since Last Earnings Report: Can It Continue? (Zacks)
Mar-20-25 05:02AM	3 Reasons CRL is Risky and 1 Stock to Buy Instead (StockStory)
Mar-11-25 08:00AM	Charles River Laboratories to Present at Barclays Global Healthcare Conference (Business Wire)
Mar-05-25 04:01AM	Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4 (StockStory)
Feb-28-25 09:35AM	Bell Global Equities Sold Charles River Laboratories International (CRL) Due To Its Potential For On-going Risk To Earnings (Insider Monkey)
Feb-25-25 11:30AM	SGH and Charles River team up for CGMP cell banking services (Hospital Management)
08:00AM	Charles River Announces Agreement with Singapore General Hospital (Business Wire)
Feb-24-25 09:15AM	Deciphering Charles River (CRL) International Revenue Trends (Zacks)
08:03AM	UFP Technologies (UFPT) Reports Q4: Everything You Need To Know Ahead Of Earnings (StockStory)
Feb-20-25 02:04AM	Charles River Laboratories International Inc (CRL) Q4 2024 Earnings Call Highlights: Navigating ... (GuruFocus.com)
12:11AM	Q4 2024 Charles River Laboratories International Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-19-25 06:08PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research) +6.87%
04:58PM	Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance (Benzinga)
09:30AM	Compared to Estimates, Charles River (CRL) Q4 Earnings: A Look at Key Metrics (Zacks)
08:10AM	Charles River Laboratories (CRL) Tops Q4 Earnings and Revenue Estimates (Zacks)
07:27AM	Charles River Laboratories (NYSE:CRL) Posts Better-Than-Expected Sales In Q4 (StockStory)
07:22AM	Charles River: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance (Business Wire)
Feb-18-25 08:03AM	Earnings To Watch: Charles River Laboratories (CRL) Reports Q4 Results Tomorrow (StockStory)
Feb-17-25 09:16AM	Gear Up for Charles River (CRL) Q4 Earnings: Wall Street Estimates for Key Metrics (Zacks)
Feb-12-25 10:00AM	Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Feb-11-25 06:41PM	Charles River Laboratories International, Inc. (CRL) Expands AI-Powered Digital Pathology Collaboration with Deciphex (Insider Monkey)
08:00AM	Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions (Business Wire)
Jan-28-25 04:30PM	Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call (Business Wire)
Jan-23-25 07:16AM	Charles River downgraded to Market Perform from Outperform at William Blair (TipRanks)
Jan-21-25 09:09AM	RiverWater Partners Sustainable Value Strategy Trimmed its Investment in Charles River Laboratories (CRL) (Insider Monkey)
08:27AM	What Makes Charles River Labs (CRL) an Investment Bet? (Insider Monkey)
08:00AM	Charles River Expands Apollo Ecosystem, Offering Bespoke Client Experiences (Business Wire)

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The Discovery and Safety Assessment segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WALLMAN RICHARD F	Former Director	Jul 21 '25	Proposed Sale	150.00	8,500	1,275,000		Jul 21 04:21 PM
WALLMAN RICHARD F	Former Director	Jun 23 '25	Proposed Sale	137.50	4,000	550,000		Jun 25 04:34 PM
MASSARO GEORGE	Director	May 15 '25	Sale	137.57	140	19,260	5,575	May 16 04:29 PM
MASSARO GEORGE	Director	May 14 '25	Sale	140.73	140	19,703	5,715	May 15 04:41 PM
LaPlume Joseph W	EVP, Corp Strategy & Develop	May 13 '25	Sale	145.41	500	72,705	19,513	May 15 04:38 PM
MASSARO GEORGE	Director	May 14 '25	Proposed Sale	140.73	280	39,405		May 14 04:05 PM
Joseph LaPlume	Officer	May 13 '25	Proposed Sale	144.32	500	72,160		May 13 03:33 PM
FOSTER JAMES C	Chairman, President and CEO	Feb 20 '25	Buy	165.01	6,075	1,002,436	183,639	Feb 21 04:41 PM
Girshick Birgit	Corporate Executive VP & COO	Feb 20 '25	Buy	164.63	1,514	249,250	55,058	Feb 21 04:38 PM
LaPlume Joseph W	EVP, Corp Strategy & Develop	Feb 20 '25	Sale	162.50	4,400	715,000	20,013	Feb 21 04:36 PM
Joseph LaPlume	Officer	Feb 20 '25	Proposed Sale	165.00	4,400	726,000		Feb 20 12:36 PM
WALLMAN RICHARD F	Director	Nov 07 '24	Sale	216.12	6,621	1,430,918	12,386	Nov 12 04:38 PM
WALLMAN RICHARD F	Director	Nov 07 '24	Sale	216.50	1,000	216,500	0	Nov 12 04:38 PM
WALLMAN RICHARD F	Director	Nov 07 '24	Proposed Sale	216.01	12,161	2,626,923		Nov 07 04:23 PM
LaPlume Joseph W	EVP, Corp Strategy & Develop	Aug 08 '24	Sale	199.36	1,780	354,861	22,521	Aug 12 04:13 PM
Joseph LaPlume	Officer	Aug 08 '24	Proposed Sale	196.63	1,780	350,000		Aug 08 01:34 PM
FOSTER JAMES C	Chairman, President and CEO	Aug 01 '24	Sale	250.00	25,000	6,250,000	188,251	Aug 05 04:04 PM
FOSTER JAMES C	Officer	Aug 01 '24	Proposed Sale	250.00	25,000	6,250,000		Aug 01 04:07 PM

Open in Screener

OABI

OmniAb Inc

Jul 25 • 04:00PM ET

2.10

Dollar change -0.02
Percentage change -0.94	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX ONC EBS FOLD KURA MGNX ADAP XBIT ONCT

| Held by: IWM VTI VXF IWN SCHA VTWO DFAT DFAS IWC VHT

Index	RUT	P/E	-	EPS (ttm)	-0.59	Insider Own	24.76%	Shs Outstand	122.13M	Perf Week	7.69%
Market Cap	256.90M	Forward P/E	-	EPS next Y	-0.45	Insider Trans	0.49%	Shs Float	91.05M	Perf Month	26.51%
Enterprise Value	235.79M	PEG	-	EPS next Q	-0.15	Inst Own	51.94%	Short Float	8.99%	Perf Quarter	15.38%
Income	-61.27M	P/S	9.61	EPS this Y	3.07%	Inst Trans	-1.02%	Short Ratio	8.62	Perf Half Y	-34.38%
Sales	26.74M	P/B	0.94	EPS next Y	23.17%	ROA	-18.60%	Short Interest	8.19M	Perf YTD	-40.68%
Book/sh	2.24	P/C	5.89	EPS next 5Y	18.68%	ROE	-21.32%	52W High	4.96 -57.66%	Perf Year	-55.60%
Cash/sh	0.36	P/FCF	-	EPS past 3/5Y	-22.79% -	ROIC	-20.97%	52W Low	1.22 72.13%	Perf 3Y	-79.19%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-8.76% -	Gross Margin	22.69%	Volatility	5.31% 6.62%	Perf 5Y	-
Dividend TTM	-	EV/Sales	8.82	EPS Y/Y TTM	6.74%	Oper. Margin	-266.93%	ATR (14)	0.12	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.70	Sales Y/Y TTM	27.07%	Profit Margin	-229.11%	RSI (14)	62.35	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.70	EPS Q/Q	8.45%	SMA20	6.33%	Beta	0.20	Target Price	8.25
Payout	-	Debt/Eq	0.08	Sales Q/Q	9.29%	SMA50	23.28%	Rel Volume	0.22	Prev Close	2.12
Employees	114	LT Debt/Eq	0.07	Earnings	Aug 06 AMC	SMA200	-26.72%	Avg Volume	949.91K	Price	2.10
IPO	Sep 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-3.79% -7.45%	Trades		Volume	205,383	Change	-0.94%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-23	Initiated	RBC Capital Mkts	Outperform	$6
Apr-21-23	Initiated	The Benchmark Company	Buy	$8
Apr-13-23	Initiated	Craig Hallum	Buy	$10
Feb-22-23	Initiated	Cowen	Outperform	$10
Feb-13-23	Initiated	H.C. Wainwright	Buy	$11
Dec-20-22	Initiated	Truist	Buy	$10
Dec-16-22	Initiated	Credit Suisse	Outperform	$13
Nov-29-22	Initiated	SVB Leerink	Outperform	$6
Nov-28-22	Initiated	Stifel	Buy	$12

Jul-16-25 08:00AM	OmniAb to Report Second Quarter 2025 Financial Results on August 6 (Business Wire)
Jun-30-25 09:50AM	AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway (PR Newswire)
May-13-25 04:05PM	OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration Platform at the 21st Annual PEGS Boston Summit (Business Wire) +8.57%
May-09-25 08:31AM	Is OmniAb, Inc. (OABI) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey) -8.28%
May-08-25 05:40PM	OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:06PM	Loading…
04:06PM	OmniAb Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
04:05PM	OmniAb Introduces the xPloration® Partner Access Program (Business Wire)
May-05-25 12:59PM	VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program (GlobeNewswire)
May-01-25 08:00AM	OmniAb to Participate in Five Upcoming Investor Conferences (Business Wire)
Apr-21-25 08:00AM	OmniAb Announces Two New Appointments to its Board of Directors (Business Wire)
Apr-14-25 08:00AM	OmniAb to Report First Quarter 2025 Financial Results on May 8 (Business Wire)
Mar-18-25 04:05PM	OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (Business Wire) -20.38%
Feb-24-25 08:00AM	OmniAb to Report Fourth Quarter 2024 Financial Results on March 18 (Business Wire)
Feb-03-25 04:57PM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-16-24 04:15PM	OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering and Therapeutics Conference (Business Wire)
04:05PM	Loading…
Nov-12-24 04:05PM	OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire) -9.35%
Oct-30-24 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Oct-22-24 08:00AM	OmniAb to Report Third Quarter 2024 Financial Results on November 12 (Business Wire)
Aug-26-24 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-08-24 04:05PM	OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire) +5.67%
Jul-25-24 08:00AM	OmniAb to Report Second Quarter 2024 Financial Results on August 8 (Business Wire)
Jun-03-24 04:05PM	OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology (Business Wire)
May-20-24 08:05AM	OmniAb to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-15-24 04:05PM	OmniAb Presents High-Throughput Single B-cell Screening xPloration Data at the 20th Annual PEGS Boston Summit (Business Wire)
May-12-24 03:24PM	5 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-09-24 08:56PM	OABI Stock Earnings: OmniAb Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	OmniAb Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
May-01-24 08:00AM	OmniAb to Participate in Five Investor Conferences in May (Business Wire)
Apr-22-24 08:00AM	OmniAb to Report First Quarter 2024 Financial Results on May 9 (Business Wire)
Mar-21-24 11:31AM	OmniAb, Inc. (NASDAQ:OABI) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.17%
08:54PM	Loading…
Mar-20-24 08:54PM	OABI Stock Earnings: OmniAb Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:05PM	OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
Feb-28-24 08:27AM	OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock? (Zacks)
Feb-26-24 08:00AM	OmniAb to Report Fourth Quarter 2023 Financial Results on March 20 (Business Wire)
Feb-20-24 08:00AM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-14-23 04:30PM	OmniAb Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference (Business Wire)
Nov-20-23 12:39PM	OmniAb, Inc. (NASDAQ:OABI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 05:03AM	Insider Buying: OmniAb Inc CEO Matthew Foehr Acquires 95,000 Shares (GuruFocus.com) +6.32%
Nov-09-23 05:55PM	OmniAb Highlights OmnidAb Launch and its Expanding Drug Discovery Platform at Todays Research & Technology Virtual Event (Business Wire)
09:24AM	OmniAb Inc (OABI) Reports Decline in Q3 Revenue and Widening Net Loss (GuruFocus.com)
08:00AM	OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights (Business Wire)
Nov-02-23 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Nov-01-23 09:00AM	OmniAb Appoints Steve Love to its Board of Directors (Business Wire)
Oct-31-23 04:28PM	OmniAb Announces Agenda for its Research & Technology Virtual Event (Business Wire)
Oct-26-23 02:32PM	7 of the Best Cheap Stocks to Buy Under $5 in October 2023 (InvestorPlace)
Oct-12-23 08:00AM	OmniAb to Hold Research & Technology Virtual Event on November 9 (Business Wire)
Sep-05-23 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-15-23 05:20AM	OmniAb, Inc. (NASDAQ:OABI) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-13-23 08:06AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Are Cutting Their Estimates: Here's What You Need To Know (Simply Wall St.)
Aug-10-23 04:05PM	OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights (Business Wire) -5.54%
Aug-07-23 04:05PM	OmniAb Announces the Passing of Director Sunil Patel (Business Wire)
Jul-31-23 08:00AM	OmniAb to Report Second Quarter 2023 Financial Results on August 10 (Business Wire)
Jul-17-23 07:35AM	With 60% institutional ownership, OmniAb, Inc. (NASDAQ:OABI) is a favorite amongst the big guns (Simply Wall St.)
Jun-13-23 06:00AM	7 Stocks to Buy for 200% Returns This Year (InvestorPlace) +6.32%
May-18-23 05:09PM	7 Stocks to Buy for Their Massive Upside Potential (InvestorPlace)
May-17-23 04:05PM	OmniAb Launches OmniDeep at the PEGS Boston Conference and Expo (Business Wire)
May-16-23 06:06AM	President of OmniAb Matthew Foehr Buys 22% More Shares \ (Simply Wall St.) +9.12%
May-14-23 08:03AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)
May-11-23 10:55PM	Q1 2023 OmniAb Inc Earnings Call (Thomson Reuters StreetEvents) +8.36%
07:00AM	OmniAb Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire)
May-05-23 07:14AM	OmniAb, Inc.'s (NASDAQ:OABI) Share Price Matching Investor Opinion (Simply Wall St.)
May-04-23 06:26AM	10 Best Small-Cap Growth Stocks to Buy Now (Insider Monkey)
May-01-23 08:00AM	OmniAb to Report First Quarter 2023 Financial Results on May 11 (Business Wire)
Apr-26-23 08:01PM	7 Biotech Stocks With Huge Return Potential for Long-Term Investors (InvestorPlace)
Apr-25-23 08:00AM	OmniAb to Participate in Upcoming Investor Conferences in May (Business Wire)
Apr-19-23 08:30AM	Here's How Much a $1000 Investment in Ligand Pharmaceuticals Made 10 Years Ago Would Be Worth Today (Zacks)
Apr-07-23 10:24PM	OmniAb, Inc. (NASDAQ:OABI) Q4 2022 Earnings Call Transcript (Insider Monkey)
Apr-05-23 06:09AM	OmniAb Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Apr-02-23 08:51AM	Insiders of OmniAb, Inc. (NASDAQ:OABI) are up 11% on their US$2.3m purchase after OmniAb, Inc. (NASDAQ:OABI) rose 14% last week (Simply Wall St.)
Mar-31-23 08:40AM	Do Options Traders Know Something About OmniAb (OABI) Stock We Don't? (Zacks)
Mar-30-23 04:05PM	OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (Business Wire)
Mar-15-23 11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-09-23 08:00AM	OmniAb to Report Fourth Quarter 2022 Financial Results on March 30 (Business Wire) -5.03%
Mar-08-23 09:53AM	These 2 Strong Buy Penny Stocks Are Poised for a Massive Rally, Say Analysts (TipRanks)
Feb-23-23 07:49AM	Ligand's (LGND) Q4 Sales & Earnings Top, View Raised, Stock Up (Zacks)
Feb-07-23 08:00AM	OmniAb to Participate in Three Upcoming Investor Conferences (Business Wire)
Feb-01-23 06:56AM	With 44% stake, OmniAb, Inc. (NASDAQ:OABI) seems to have captured institutional investors' interest (Simply Wall St.)
Dec-16-22 12:39PM	Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says (Benzinga)
Dec-01-22 08:47AM	Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies (HSB-1940) against PD-1, by combining Quatramers with OmniAbs Picobodies, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets (GlobeNewswire) -5.37%
Nov-15-22 07:00AM	OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights (Business Wire) -10.00%
Nov-03-22 08:00AM	OmniAb to Participate in Two Upcoming Investor Conferences (Business Wire)
Nov-02-22 07:00AM	OmniAb, Inc. to Ring Nasdaq Stock Market Opening Bell (Business Wire) -60.65%
Nov-01-22 04:01PM	OmniAb Announces Completion of Spin-Off and Business Combination (Business Wire) -9.26%
04:01PM	Ligand Announces Completion of OmniAb Spin-Off (Business Wire)

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cochran Jennifer R.	Director	May 15 '25	Buy	1.52	30,000	45,600	145,274	May 15 04:02 PM
Love Steven	Director	May 14 '25	Buy	1.46	25,000	36,500	38,333	May 14 05:04 PM
HIGGINS JOHN L	Director	May 12 '25	Buy	1.44	65,000	93,600	2,831,887	May 13 05:52 PM
FOEHR MATTHEW W	President and CEO	Apr 07 '25	Option Exercise	0.00	36,458	0	3,815,618	Apr 07 08:17 PM
FOEHR MATTHEW W	President and CEO	Apr 07 '25	Sale	2.00	19,382	38,764	3,796,236	Apr 07 08:17 PM
Berkman Charles S	Chief Legal Officer	Apr 07 '25	Option Exercise	0.00	13,542	0	370,418	Apr 07 08:10 PM
Berkman Charles S	Chief Legal Officer	Apr 07 '25	Sale	2.00	7,206	14,412	363,212	Apr 07 08:10 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 07 '25	Option Exercise	0.00	13,542	0	231,034	Apr 07 08:09 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 07 '25	Sale	2.00	7,206	14,412	223,828	Apr 07 08:09 PM
GUSTAFSON KURT A	Officer	Apr 07 '25	Proposed Sale	2.00	7,206	14,396		Apr 07 08:04 PM
FOEHR MATTHEW W	Officer	Apr 07 '25	Proposed Sale	2.00	19,382	38,715		Apr 07 08:00 PM
Berkman Charles S	Officer	Apr 07 '25	Proposed Sale	2.00	7,206	14,396		Apr 07 07:56 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 01 '25	Option Exercise	0.00	23,244	0	229,455	Apr 01 08:43 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 01 '25	Sale	2.37	11,963	28,352	217,492	Apr 01 08:43 PM
GUSTAFSON KURT A	Officer	Apr 01 '25	Proposed Sale	2.37	11,963	28,351		Apr 01 07:16 PM
HIGGINS JOHN L	Director	Mar 21 '25	Buy	2.28	4,000	9,120	2,766,887	Mar 21 07:58 PM
HIGGINS JOHN L	Director	Mar 20 '25	Buy	2.35	125,750	295,512	2,762,887	Mar 20 08:15 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 16 '25	Option Exercise	0.00	13,541	0	213,466	Feb 19 08:51 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 19 '25	Sale	3.67	7,255	26,626	206,211	Feb 19 08:51 PM
FOEHR MATTHEW W	President and CEO	Feb 19 '25	Sale	3.67	19,522	71,646	3,779,160	Feb 19 08:51 PM
FOEHR MATTHEW W	President and CEO	Feb 18 '25	Sale	3.68	13,964	51,388	3,798,682	Feb 19 08:51 PM
Berkman Charles S	Chief Legal Officer	Feb 18 '25	Sale	3.68	8,215	30,231	364,131	Feb 19 08:50 PM
Berkman Charles S	Chief Legal Officer	Feb 19 '25	Sale	3.67	7,255	26,626	356,876	Feb 19 08:50 PM
GUSTAFSON KURT A	Officer	Feb 19 '25	Proposed Sale	3.68	5,188	19,092		Feb 18 08:36 PM
FOEHR MATTHEW W	Officer	Feb 18 '25	Proposed Sale	3.68	13,964	51,390		Feb 18 08:30 PM
Berkman Charles S	Officer	Feb 18 '25	Proposed Sale	3.68	8,215	30,232		Feb 18 08:28 PM
Berkman Charles S	Chief Legal Officer	Jan 21 '25	Sale	3.24	25,489	82,584	343,190	Jan 22 05:41 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Jan 21 '25	Sale	3.24	15,526	50,304	212,720	Jan 22 05:40 PM
FOEHR MATTHEW W	President and CEO	Jan 21 '25	Sale	3.24	41,811	135,468	3,749,639	Jan 22 05:40 PM
FOEHR MATTHEW W	Officer	Jan 21 '25	Proposed Sale	3.24	41,811	135,378		Jan 21 07:25 PM
Berkman Charles S	Officer	Jan 21 '25	Proposed Sale	3.24	25,489	82,529		Jan 21 07:24 PM
GUSTAFSON KURT A	Officer	Jan 21 '25	Proposed Sale	3.24	15,526	50,271		Jan 21 07:22 PM
Berkman Charles S	Chief Legal Officer	Dec 09 '24	Sale	4.13	8,022	33,131	323,385	Dec 10 04:47 PM
FOEHR MATTHEW W	President and CEO	Dec 09 '24	Sale	4.13	13,634	56,308	3,714,447	Dec 10 04:44 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Dec 09 '24	Sale	4.13	23,871	98,587	200,661	Dec 10 04:41 PM
GUSTAFSON KURT A	Officer	Dec 09 '24	Proposed Sale	4.13	23,871	98,476		Dec 09 08:49 PM
FOEHR MATTHEW W	Officer	Dec 09 '24	Proposed Sale	4.13	13,634	56,245		Dec 09 08:45 PM
Berkman Charles S	Officer	Dec 09 '24	Proposed Sale	4.13	8,022	33,094		Dec 09 08:41 PM
FOEHR MATTHEW W	President and CEO	Nov 25 '24	Option Exercise	3.73	99,434	370,702	3,698,600	Nov 26 04:41 PM

NRC National Research Corp daily Stock Chart

Peers: STAA EHC ACHC SMLR MD SGRY HCSG HQY ENSV SGRP

| Held by: VTI IWM VXF DES IWO VTWO SCHA DFAS RFDA DGRS

Index	RUT	P/E	13.48	EPS (ttm)	1.03	Insider Own	46.02%	Shs Outstand	22.79M	Perf Week	-2.32%
Market Cap	316.49M	Forward P/E	-	EPS next Y	-	Insider Trans	0.02%	Shs Float	12.30M	Perf Month	-17.52%
Enterprise Value	379.19M	PEG	-	EPS next Q	-	Inst Own	50.60%	Short Float	3.30%	Perf Quarter	29.87%
Income	24.21M	P/S	2.24	EPS this Y	-	Inst Trans	-6.81%	Short Ratio	4.25	Perf Half Y	-23.05%
Sales	141.30M	P/B	10.67	EPS next Y	-	ROA	18.91%	Short Interest	0.41M	Perf YTD	-21.26%
Book/sh	1.30	P/C	126.60	EPS next 5Y	-	ROE	72.68%	52W High	27.07 -48.69%	Perf Year	-43.49%
Cash/sh	0.11	P/FCF	21.18	EPS past 3/5Y	-10.60% -3.68%	ROIC	27.41%	52W Low	9.76 42.39%	Perf 3Y	-62.49%
Dividend Est.	-	EV/EBITDA	9.17	Sales past 3/5Y	-1.11% 2.25%	Gross Margin	55.94%	Volatility	3.94% 4.47%	Perf 5Y	-76.05%
Dividend TTM	0.48 (3.46%)	EV/Sales	2.68	EPS Y/Y TTM	-17.17%	Oper. Margin	24.95%	ATR (14)	0.66	Perf 10Y	-2.69%
Dividend Ex-Date	Jun 27, 2025	Quick Ratio	0.54	Sales Y/Y TTM	-4.15%	Profit Margin	17.13%	RSI (14)	35.08	Recom	3.00
Dividend Gr. 3/5Y	0.00% -9.25%	Current Ratio	0.54	EPS Q/Q	-5.05%	SMA20	-10.83%	Beta	0.46	Target Price	44.00
Payout	45.99%	Debt/Eq	2.20	Sales Q/Q	-4.99%	SMA50	-8.75%	Rel Volume	0.45	Prev Close	14.12
Employees	368	LT Debt/Eq	1.98	Earnings	-	SMA200	-13.44%	Avg Volume	95.62K	Price	13.89
IPO	May 23, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	- -	Trades		Volume	42,798	Change	-1.63%

Jun-26-25 02:16AM	National Research Solidifies Dividend Amid Insider Buying and Contract Growth (Insider Monkey)
May-02-25 01:13PM	NRC Q1 Earnings Dip Y/Y Amid Rising Interest Costs, Shares Up 13% (Zacks) +5.41%
Apr-28-25 05:00PM	NRC Health Announces First Quarter Results (Business Wire) +9.50%
Apr-10-25 02:01PM	A New Era of Trust: NRC Healths 2025 Experience Perspective Report Reveals Insights to Elevate the Healthcare Experience (Business Wire) -10.78%
Mar-24-25 05:00PM	National Research Corporation Declares Quarterly Dividend (Business Wire) -6.57%
07:23AM	Loading…
07:23AM	The Zacks Analyst Blog Philip Morris, Booking Holdings, Anheuser-Busch InBev, Elite Pharmaceuticals and National Research (Zacks)
Mar-21-25 06:18PM	Top Stock Reports for Philip Morris, Booking Holdings & Anheuser-Busch (Zacks)
Mar-04-25 04:01PM	National Research Corporation Appoints Trent Green as Chief Executive Officer (Business Wire)
Feb-25-25 08:03AM	UofL Health Chooses NRC Health to Elevate Patient and Employee Experience Initiatives (Business Wire)
Feb-11-25 09:01AM	NRC Health Partners with UC Health to Enhance Healthcare Consumer Experience (Business Wire)
Feb-05-25 08:01AM	NRC Health ranked #1 Best in KLAS for Healthcare Experience Management (Business Wire)
Jan-27-25 05:00PM	National Research Corporation Announces Fourth Quarter Results (Business Wire) -11.85%
Jan-07-25 12:00PM	Renown Health selects NRC Health as partner to enhance patient experience and operational efficiency (Business Wire)
Nov-20-24 09:02AM	Signature Healthcare Elevates Patient Experience and Workforce Engagement Through Strategic Partnership With NRC Health (Business Wire)
Nov-12-24 09:02AM	Cooper University Health Care Selects NRC Health as New Patient Experience Partner (Business Wire)
05:00PM	Loading…
Oct-25-24 05:00PM	National Research Corporation Announces Third Quarter Results (Business Wire)
Aug-22-24 01:00PM	AI meets empathy: NRC Health launches first AI-enabled solutions to elevate healthcare experience (Business Wire)
Aug-06-24 05:00PM	National Research Corporation Announces Second Quarter Results (Business Wire) -9.54%
May-07-24 05:00PM	National Research Corporation Announces First Quarter Results (Business Wire) -16.47%
Apr-18-24 04:23PM	National Research Corporation to Broadcast Its First Quarter 2024 Conference Call Live on the Internet (Business Wire)
Apr-02-24 11:55AM	Veteran Patient Experience Executive Jennifer Baron Joins NRC Health as Its First Chief Experience Officer (Business Wire) -7.02%
Feb-13-24 05:33PM	National Research Corp (NRC) Reports Q4 and Full-Year 2023 Financial Results (GuruFocus.com) +6.13%
05:00PM	National Research Corporation Announces Fourth Quarter and Calendar Year 2023 Results (Business Wire)
Feb-01-24 03:00PM	National Research Corporation to Broadcast Its Fourth Quarter and Year-end 2023 Conference Call Live on the Internet (Business Wire)
10:00AM	NRC Health Expands Leadership Team to Accelerate Innovation, Meet Growing Demand for Insights and Solutions (Business Wire)
Jan-31-24 10:00AM	Yuma Regional Medical Center Selects NRC Health as New Patient Experience Partner (Business Wire)
Jan-17-24 03:00PM	National Research Corporation Elevates Leadership Team to Seize Growth Opportunity (Business Wire)
Nov-17-23 05:00PM	National Research Corporation Declares Quarterly Dividend (GlobeNewswire)
Nov-09-23 02:08PM	National Research Corporation (NASDAQ:NRC) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 05:00PM	National Research Corporation Announces Third Quarter 2023 Results (GlobeNewswire)
04:00PM	Loading…
Oct-24-23 04:00PM	National Research Corporation to Broadcast its 2023 Third Quarter Conference Call Live on the Internet (GlobeNewswire)
Sep-26-23 08:55AM	Lurie Childrens expands partnership with NRC Health to gain valuable consumer insights (GlobeNewswire)
Sep-06-23 05:00PM	National Research Corporation Declares Special Dividend (GlobeNewswire)
Aug-31-23 06:55AM	NRC Health emphasizes its commitment to ICDs annual Patient Experience Symposium (GlobeNewswire)
Aug-29-23 08:55AM	LifeBridge Health selects NRC Health as its new patient experience partner (GlobeNewswire)
Aug-21-23 05:00PM	National Research Corporation Declares Quarterly Dividend (GlobeNewswire)
Aug-08-23 12:33PM	NRC Health unveils winners of 2023 patient experience and loyalty awards (GlobeNewswire)
Aug-01-23 05:00PM	National Research Corporation Announces Second Quarter 2023 Results (GlobeNewswire)
Jul-26-23 09:28AM	National Research (NASDAQ:NRC) Is Achieving High Returns On Its Capital (Simply Wall St.)
Jul-18-23 04:00PM	National Research Corporation to Broadcast its 2023 Second Quarter Conference Call Live on the Internet (GlobeNewswire)
Jul-12-23 11:51AM	Bryan Health Chooses NRC Health as Patient Experience Partner (GlobeNewswire)
May-31-23 12:50PM	NRC Health partners with ICD as lead sponsor of 7th Annual Patient Experience Symposium (GlobeNewswire)
May-25-23 05:00PM	National Research Corporation Declares Quarterly Dividend (GlobeNewswire)
May-12-23 02:16PM	UCHealth Partners with NRC Health to Improve Healthcare Experiences (GlobeNewswire)
May-02-23 05:00PM	National Research Corporation Announces First Quarter 2023 Results (GlobeNewswire) -7.63%
Apr-18-23 05:18PM	National Research Corporation to Broadcast its 2023 First Quarter Conference Call Live on the Internet (GlobeNewswire)
Apr-06-23 10:00AM	NRC Health reveals 2023 Pediatric Experience Perspective (GlobeNewswire)
Mar-30-23 10:00AM	NRC Health energizes healthcare organizations with digital solution to ease burnout for care teams (GlobeNewswire)
Mar-02-23 01:21PM	NRC Health offers first-of-its-kind patient experience EHR integration (GlobeNewswire)
Feb-15-23 01:00PM	Keys to delivering humanized care revealed in NRC Healths 2023 Experience Perspective (GlobeNewswire) +5.42%
Feb-14-23 05:00PM	National Research Corporation Announces Fourth Quarter and Calendar Year 2022 Results (GlobeNewswire)
Feb-08-23 08:01AM	NRC Health recognized as Best in KLAS for Patient Experience Improvement (GlobeNewswire)
Feb-03-23 05:00PM	National Research Corporation Declares Quarterly Dividend (GlobeNewswire)
Jan-30-23 03:34PM	National Research Corporation to Broadcast its 2022 Fourth Quarter Conference Call Live on the Internet (GlobeNewswire)
Nov-11-22 05:00PM	National Research Corporation Declares Quarterly Dividend (GlobeNewswire) -6.56%
Nov-09-22 05:12AM	National Research Third Quarter 2022 Earnings: EPS: US$0.34 (vs US$0.38 in 3Q 2021) (Simply Wall St.)
Nov-01-22 05:00PM	National Research Corporation Announces Third Quarter 2022 Results (GlobeNewswire) -13.16%
09:00AM	NRC Health Study Finds Trust in Local Hospitals and Health Systems Increased During the Pandemic (GlobeNewswire)
Oct-19-22 02:49PM	National Research Corporation to Broadcast its 2022 Third Quarter Conference Call Live on the Internet (GlobeNewswire)
Sep-29-22 09:00AM	NRC Health Announces Sponsorship of Creative Learning Event Series Hosted by the Society for Participatory Medicine (GlobeNewswire)
Aug-23-22 05:00PM	National Research Corporation Declares Quarterly Dividend (GlobeNewswire)
Aug-16-22 02:38PM	NRC Health Unveils Winners of 2022 Annual Awards Programs (GlobeNewswire)
Aug-12-22 11:16AM	NRC Health Announces Partnership with The Beryl Institute (GlobeNewswire)
Aug-02-22 05:00PM	National Research Corporation Announces Second Quarter 2022 Results (GlobeNewswire)
Jul-19-22 04:12PM	National Research Corporation to Broadcast its 2022 Second Quarter Conference Call Live on the Internet (GlobeNewswire)
Jul-11-22 08:03AM	National Research Corporation (NASDAQ:NRC) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? (Simply Wall St.)
Jun-30-22 09:00AM	CISOs Connect Names NRC Health Chief Security and Privacy Officer Among 2022 Top 100 CISOs in the Country (GlobeNewswire)
Jun-10-22 10:12AM	We Like National Research's (NASDAQ:NRC) Returns And Here's How They're Trending (Simply Wall St.)
May-23-22 10:07AM	We Think National Research (NASDAQ:NRC) Can Manage Its Debt With Ease (Simply Wall St.)
May-20-22 05:00PM	National Research Corporation Announces Quarterly Dividend and Stock Repurchase Authorization (GlobeNewswire)
May-19-22 09:00AM	National Research Corporation Announces Appointment to Board of Directors (GlobeNewswire)
May-04-22 08:42AM	National Research's (NASDAQ:NRC) five-year total shareholder returns outpace the underlying earnings growth (Simply Wall St.)
May-03-22 05:00PM	National Research Corporation Announces First Quarter 2022 Results (GlobeNewswire)
Apr-19-22 04:35PM	National Research Corporation to Broadcast its 2022 First Quarter Conference Call Live on the Internet (GlobeNewswire)
Mar-26-22 02:24PM	Is It Smart To Buy National Research Corporation (NASDAQ:NRC) Before It Goes Ex-Dividend? (Simply Wall St.)
Mar-16-22 10:21AM	Second Annual Report from NRC Health Highlights Major Trends in Pediatric Care (GlobeNewswire)
Mar-03-22 10:21AM	What Is The Ownership Structure Like For National Research Corporation (NASDAQ:NRC)? (Simply Wall St.)
Feb-14-22 05:00PM	NRC Health Declares Quarterly Dividend (GlobeNewswire) +5.30%
Feb-08-22 05:00PM	National Research Corporation Announces Fourth Quarter and Calendar Year 2021 Results (GlobeNewswire)
Feb-01-22 11:13AM	National Research Corporation (NASDAQ:NRC) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? (Simply Wall St.) -5.87%
Jan-27-22 12:44PM	National Research Corporation to Broadcast its 2021 Fourth Quarter Conference Call Live on the Internet (GlobeNewswire)
Jan-26-22 09:38AM	Touchstone Capital, Inc. Buys Coinbase Global Inc, National Research Corp, Pfizer Inc, Sells T. ... (GuruFocus.com)
Jan-19-22 10:00AM	NRC Health Annual Consumer Trends Report Shows Declining Care Deferment, Rising Mental Health Challenges and Gaps in Telehealth (GlobeNewswire)
Dec-10-21 04:37PM	The Governance Institute Releases 2021 National Survey of Healthcare Governance (GlobeNewswire)
07:47AM	National Research (NASDAQ:NRC) Is Achieving High Returns On Its Capital (Simply Wall St.)
Nov-19-21 05:11PM	National Research Corporation Declares Quarterly Dividend (GlobeNewswire)
Nov-17-21 09:35AM	NRC Health Awards Annual Scholarship to UNL Students (GlobeNewswire)
Nov-04-21 01:35PM	We Think National Research (NASDAQ:NRC) Can Manage Its Debt With Ease (Simply Wall St.)
Nov-02-21 05:00PM	National Research Corporation Announces Third Quarter 2021 Results (GlobeNewswire)
09:00AM	NRC Health Wins Five 2021 MarCom Awards (GlobeNewswire)
Oct-05-21 09:59AM	National Research (NASDAQ:NRC) sheds 5.7% this week, as yearly returns fall more in line with earnings growth (Simply Wall St.)
Aug-30-21 09:04AM	Calculating The Intrinsic Value Of National Research Corporation (NASDAQ:NRC) (Simply Wall St.)
Aug-20-21 05:00PM	National Research Corporation Declares Quarterly Dividend (GlobeNewswire)
Aug-06-21 09:00AM	NRC Health Announces Winner of 2021 Excellence in Human Understanding Award (GlobeNewswire)
Aug-05-21 02:00PM	NRC Health Names Honorees of 2021 Excellence Awards (GlobeNewswire)
09:00AM	NRC Health Names Consumer Loyalty Award Winners at 27th Annual Symposium (GlobeNewswire)
Aug-03-21 05:00PM	National Research Corporation Announces Second Quarter 2021 Results (GlobeNewswire)
Jul-26-21 07:14AM	Are Strong Financial Prospects The Force That Is Driving The Momentum In National Research Corporation's NASDAQ:NRC) Stock? (Simply Wall St.)
Jul-08-21 04:15PM	NRC Healths Chief Security and Privacy Officer Recognized as One of the Top 100 CISOs in the Country (GlobeNewswire)
Jun-24-21 04:30AM	National Research Corporation (NASDAQ:NRC) Looks Like A Good Stock, And It's Going Ex-Dividend Soon (Simply Wall St.)

National Research Corp. engages in the provision of analytics and insights that facilitate patient, employee, and customer retention. It offers solutions that address specific needs around market insight, experience, transparency, and governance for healthcare providers, payers, and other healthcare organizations. The company was founded by Michael D. Hays in 1981 and is headquartered in Lincoln, NE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BEANS PATRICK E	10% Owner	May 12 '25	Buy	13.59	2,500	33,974	35,003	May 13 11:30 AM
Hays Michael D.	CEO & President	Jan 02 '25	Option Exercise	13.17	10,014	131,884	11,009	Jan 06 04:18 PM

MEDP Medpace Holdings Inc daily Stock Chart

Peers: IQV CRL INCY LH ICON CTLT KOD FATE ALLO ONC

| Held by: IJH VTI VB XMHQ VXF VBK MDY IWP IBB IJK

Index	-	P/E	33.28	EPS (ttm)	13.45	Insider Own	19.38%	Shs Outstand	28.02M	Perf Week	43.49%
Market Cap	12.57B	Forward P/E	29.32	EPS next Y	15.26	Insider Trans	-0.10%	Shs Float	22.65M	Perf Month	43.82%
Enterprise Value	12.67B	PEG	3.47	EPS next Q	3.47	Inst Own	92.55%	Short Float	13.50%	Perf Quarter	47.74%
Income	418.30M	P/S	5.63	EPS this Y	9.22%	Inst Trans	0.09%	Short Ratio	6.31	Perf Half Y	28.63%
Sales	2.23B	P/B	72.75	EPS next Y	10.65%	ROA	23.96%	Short Interest	3.06M	Perf YTD	34.69%
Book/sh	6.15	P/C	271.34	EPS next 5Y	9.59%	ROE	89.38%	52W High	501.30 -10.73%	Perf Year	25.24%
Cash/sh	1.65	P/FCF	21.68	EPS past 3/5Y	37.94% 36.50%	ROIC	140.70%	52W Low	250.05 78.96%	Perf 3Y	184.52%
Dividend Est.	-	EV/EBITDA	25.03	Sales past 3/5Y	22.68% 19.62%	Gross Margin	30.32%	Volatility	7.74% 3.97%	Perf 5Y	323.72%
Dividend TTM	-	EV/Sales	5.68	EPS Y/Y TTM	25.30%	Oper. Margin	21.40%	ATR (14)	24.74	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.43	Sales Y/Y TTM	9.94%	Profit Margin	18.74%	RSI (14)	71.67	Recom	3.07
Dividend Gr. 3/5Y	- -	Current Ratio	0.43	EPS Q/Q	12.47%	SMA20	29.46%	Beta	1.45	Target Price	417.90
Payout	0.00%	Debt/Eq	0.87	Sales Q/Q	14.24%	SMA50	40.23%	Rel Volume	1.57	Prev Close	455.68
Employees	5900	LT Debt/Eq	0.72	Earnings	Jul 21 AMC	SMA200	36.77%	Avg Volume	484.87K	Price	447.49
IPO	Aug 11, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.94% 11.98%	Trades		Volume	763,590	Change	-1.80%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-23-25	Downgrade	TD Cowen	Hold → Sell	$366
Jun-24-25	Initiated	Barclays	Equal Weight	$300
Apr-22-25	Downgrade	William Blair	Outperform → Mkt Perform
Apr-14-25	Downgrade	TD Cowen	Buy → Hold	$328
Mar-24-25	Initiated	Leerink Partners	Market Perform	$330
Oct-23-24	Downgrade	Robert W. Baird	Outperform → Neutral	$413 → $349
Oct-14-24	Initiated	Redburn Atlantic	Buy
Sep-27-24	Downgrade	UBS	Buy → Neutral	$420 → $350
Sep-25-24	Downgrade	Jefferies	Buy → Hold	$415 → $345
Aug-01-24	Initiated	Truist	Hold	$415
May-29-24	Initiated	TD Cowen	Buy	$452
May-28-24	Initiated	Mizuho	Buy	$435
Apr-23-24	Upgrade	Jefferies	Hold → Buy	$340 → $450
Mar-18-24	Initiated	Deutsche Bank	Hold	$395
Feb-15-24	Upgrade	UBS	Neutral → Buy	$282 → $452
Oct-24-23	Upgrade	Robert W. Baird	Neutral → Outperform	$270 → $289
May-08-23	Upgrade	Guggenheim	Neutral → Buy	$252
Oct-27-22	Upgrade	UBS	Sell → Neutral	$142 → $238
Sep-07-22	Initiated	UBS	Sell	$142
May-24-22	Initiated	Guggenheim	Neutral

Show Previous Ratings

Jul-25-25 07:48PM	Medpace Holdings, Inc. (MEDP): A Bull Case Theory (Insider Monkey)
08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Jul-23-25 01:11PM	Medpace (MEDP) Stock Trades Down, Here Is Why (StockStory) -8.44%
10:37AM	Analyst Report: Medpace Holdings, Inc. (Morningstar Research)
03:09AM	Medpace Holdings Inc (MEDP) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ... (GuruFocus.com)
06:47PM	Loading…
Jul-22-25 06:47PM	Analyst Report: Medpace Holdings, Inc. (Morningstar Research) +54.67%
04:06PM	Medpace Surges 55% On 'Shockingly Strong' Report; Pulling Iqvia Higher (Investor's Business Daily)
02:44PM	MEDP Q2 Deep Dive: Backlog Conversion, Lower Cancellations, and Therapeutic Mix Drive Outlook (StockStory)
11:55AM	Why Is Medpace (MEDP) Stock Rocketing Higher Today (StockStory)
11:15AM	Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y (Zacks)
10:47AM	Stock Market Today: Dow Struggles, Nasdaq Drops From New High; Medical Services Name Surges On Earnings (Live Coverage) (Investor's Business Daily)
07:36AM	This Clinical Trials Stock Just Soared 40%. What Caused It to Pop. (Barrons.com)
05:12AM	Opendoor Technologies shares bounce again after turbulent trading (MarketWatch)
Jul-21-25 05:25PM	Medpace (MEDP) Q2 Earnings and Revenues Surpass Estimates (Zacks)
04:43PM	Medpace (NASDAQ:MEDP) Reports Strong Q2, Stock Jumps 46% (StockStory)
04:20PM	Loading…
04:20PM	Medpace: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	Medpace Holdings, Inc. Reports Second Quarter 2025 Results (Business Wire)
11:40AM	OGN or MEDP: Which Is the Better Value Stock Right Now? (Zacks)
Jul-19-25 11:01PM	Medpace (MEDP) Q2 Earnings Report Preview: What To Look For (StockStory)
Jul-17-25 06:15PM	Medpace (MEDP) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
Jul-16-25 10:00AM	Analysts Estimate Icon PLC (ICLR) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-14-25 10:00AM	Medpace (MEDP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-10-25 06:15PM	Medpace (MEDP) Exceeds Market Returns: Some Facts to Consider (Zacks)
Jul-09-25 12:12PM	Brookdale's Occupancy Registers a Rise to 80.5% in June 2025 (Zacks)
Jul-08-25 01:06PM	Motley Fool Investors Look Back at the First Half of 2025 (Motley Fool)
Jul-03-25 11:40AM	OGN vs. MEDP: Which Stock Is the Better Value Option? (Zacks)
Jul-02-25 06:15PM	Medpace (MEDP) Exceeds Market Returns: Some Facts to Consider (Zacks)
Jun-26-25 06:15PM	Medpace (MEDP) Stock Dips While Market Gains: Key Facts (Zacks)
Jun-24-25 11:31PM	Reflecting On Drug Development Inputs & Services Stocks' Q1 Earnings: Medpace (NASDAQ:MEDP) (StockStory)
Jun-23-25 04:05PM	Medpace Holdings, Inc. to Report Second Quarter 2025 Financial Results on July 21, 2025 (Business Wire)
12:05AM	Loading…
Jun-18-25 12:05AM	2 Reasons to Watch MEDP and 1 to Stay Cautious (StockStory)
Jun-17-25 06:15PM	Medpace (MEDP) Dips More Than Broader Market: What You Should Know (Zacks)
08:07AM	The 5 Most Interesting Analyst Questions From Medpace's Q1 Earnings Call (StockStory)
Jun-10-25 06:15PM	Medpace (MEDP) Exceeds Market Returns: Some Facts to Consider (Zacks)
Jun-09-25 11:40AM	CON or MEDP: Which Is the Better Value Stock Right Now? (Zacks)
May-27-25 07:00PM	Is Medpace Stock Worth the Hype? Here's What Analysts Think. (Motley Fool)
May-21-25 11:27AM	Medpace Holdings, Inc. (MEDP): A Bull Case Theory (Insider Monkey)
May-14-25 11:40AM	CON vs. MEDP: Which Stock Is the Better Value Option? (Zacks) -5.94%
May-13-25 06:20AM	Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar? (Zacks)
Apr-30-25 04:33AM	Is Healthcare Losing the Status of Safe Haven? ETFs in Focus (Zacks)
Apr-28-25 08:46PM	Analyst Report: Medpace Holdings, Inc. (Morningstar Research)
11:59AM	Healthcare stocks: No longer a safe space for investors? (Yahoo Finance)
11:40AM	CON or MEDP: Which Is the Better Value Stock Right Now? (Zacks)
03:08AM	Repligen (RGEN) Q1 Earnings: What To Expect (StockStory)
Apr-25-25 12:09PM	Healthcare sector under pressure as market weighs Trump impact (Yahoo Finance Video)
Apr-24-25 10:08AM	MEDP Q1 Earnings Call: Revenue Beats Expectations Amid Cancellations and Industry Headwinds (StockStory)
07:35AM	Giverny Capital Asset Management Q1 2025 Letter (Seeking Alpha)
Apr-23-25 03:04AM	Medpace Holdings Inc (MEDP) Q1 2025 Earnings Call Highlights: Revenue Growth Amidst Competitive ... (GuruFocus.com)
12:15AM	Q1 2025 Medpace Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-22-25 04:03PM	Medpace Hits 17-Month Low After Bookings Miss Leaves Investors Mystified (Investor's Business Daily)
03:42PM	Medpace Holdings, Inc. (MEDP) Q1 2025 Earnings Call Transcript (Seeking Alpha)
03:21PM	Analyst Report: Medpace Holdings, Inc. (Morningstar Research)
02:32PM	Why Medpace (MEDP) Stock Is Trading Lower Today (StockStory)
Apr-21-25 05:25PM	Medpace (MEDP) Q1 Earnings and Revenues Beat Estimates (Zacks)
04:24PM	Medpace (NASDAQ:MEDP) Beats Expectations in Strong Q1 But Stock Drops (StockStory)
04:21PM	Medpace: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Medpace Holdings, Inc. Reports First Quarter 2025 Results (Business Wire)
Apr-20-25 08:00AM	Medpace (MEDP) Q1 Earnings: What To Expect (StockStory)
Apr-18-25 08:31AM	What Makes Medpace Holdings (MEDP) a Better Investment? (Insider Monkey)
Apr-15-25 10:00AM	Elevance Health (ELV) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
08:55AM	What Makes Medpace Holdings (MEDP) an Investment Bet? (Insider Monkey)
Apr-14-25 10:00AM	Analysts Estimate Medpace (MEDP) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-11-25 11:40AM	CON vs. MEDP: Which Stock Is the Better Value Option? (Zacks) +5.45%
Apr-10-25 09:13AM	Strength Seen in Organon (OGN): Can Its 8.5% Jump Turn into More Strength? (Zacks) -6.69%
06:15AM	Vulcan Value Partners Q1 2025 Letter (Seeking Alpha)
05:08AM	Medpace (MEDP) Surges 9.1%: Is This an Indication of Further Gains? (Zacks)
Apr-07-25 06:15PM	Medpace (MEDP) Ascends While Market Falls: Some Facts to Note (Zacks)
Apr-05-25 06:58AM	1 Spectacular Growth Stock Down 34% to Buy Hand Over Fist (Motley Fool)
Apr-04-25 09:14AM	Medpace Holdings, Inc. (MEDP): A Bull Case Theory (Insider Monkey) -5.59%
08:14AM	Medpace Holdings: It Might Be Time To Buy In (Seeking Alpha)
Apr-02-25 08:00AM	Icon Plc: The Sale Was Well-Timed (Seeking Alpha)
06:00AM	LVS Advisory Q1 2025 Letter (Seeking Alpha)
Mar-28-25 03:59PM	Baird Q4 2024 Small/Mid Cap Growth Equity Commentary (Seeking Alpha)
Mar-27-25 07:05PM	Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
06:37PM	Analyst Report: Medpace Holdings, Inc. (Morningstar Research)
Mar-24-25 06:15PM	Medpace (MEDP) Outperforms Broader Market: What You Need to Know (Zacks)
12:33PM	Is Medpace Holdings, Inc. (MEDP) the Best Diagnostics Stock to Invest in Right Now? (InsiderMonkey)
11:40AM	CON or MEDP: Which Is the Better Value Stock Right Now? (Zacks)
Mar-21-25 05:03AM	Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers (StockStory)
Mar-18-25 04:05PM	Medpace Holdings, Inc. to Report First Quarter 2025 Financial Results on April 21, 2025 (Business Wire)
Mar-03-25 04:04AM	2 Reasons to Watch MEDP and 1 to Stay Cautious (StockStory)
Feb-17-25 08:55AM	Here are the Reasons to Invest in Medpace Holdings (MEDP) (Insider Monkey)
Feb-14-25 08:00AM	Medpace Holdings, Inc. (MEDP): A Bull Case Theory (Insider Monkey)
Feb-12-25 09:12AM	Analyst Report: Medpace Holdings, Inc. (Morningstar Research)
02:08AM	Medpace Holdings Inc (MEDP) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
12:06AM	Q4 2024 Medpace Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-11-25 11:54AM	Why Medpace (MEDP) Shares Are Trading Lower Today (StockStory) -7.52%
Feb-10-25 04:39PM	Medpace: Q4 Earnings Snapshot (Associated Press Finance)
04:33PM	Medpace (NASDAQ:MEDP) Posts Q4 Sales In Line With Estimates But Stock Drops (StockStory)
04:15PM	Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Results (Business Wire)
Feb-09-25 08:03AM	Medpace (MEDP) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Feb-07-25 08:14AM	Here are Giverny Capital Asset Managements Updates on Medpace Holdings (MEDP) (Insider Monkey)
Jan-20-25 08:55AM	What Makes Medpace Holdings (MEDP) a Promising Investment? (Insider Monkey)
Jan-03-25 08:27AM	Lower than Expected Results Dragged Medpace Holdings (MEDP) in Q3 (Insider Monkey)
Jan-02-25 04:05PM	Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 10, 2025 (Business Wire)
Nov-21-24 06:52PM	Analyst Report: Medpace Holdings, Inc. (Morningstar Research)
Nov-15-24 06:47PM	Analyst Report: Medpace Holdings, Inc. (Morningstar Research) -7.23%
Nov-06-24 06:36PM	Analyst Report: Medpace Holdings, Inc. (Morningstar Research) +9.15%
Nov-04-24 10:12AM	What Makes Medpace Holdings (MEDP) a Good Holding? (Insider Monkey)
Nov-01-24 07:33PM	Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Medpace Holdings, Inc. for potential violations of securities laws (GlobeNewswire)

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The firm's services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. It operates through the following geographical segments: United States, Europe, Belgium, Asia-Pacific, and Other. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McCarthy Cornelius P. III	Director	Jul 22 '25	Option Exercise	54.99	1,972	108,440	11,859	Jul 24 04:31 PM
Brady Kevin M.	Officer	Jul 24 '25	Proposed Sale	454.23	12,000	5,450,751		Jul 24 04:13 PM
GEIGER JESSE J	Officer	Jul 24 '25	Proposed Sale	453.11	41,801	18,940,252		Jul 24 04:09 PM
McCarthy Cornelius P. III	Director	Jul 18 '25	Option Exercise	54.99	4,500	247,455	9,887	Jul 22 04:36 PM
DAVENPORT FRED B JR	Director	Apr 24 '25	Option Exercise	57.17	4,710	269,271	4,710	Apr 28 04:39 PM
DAVENPORT FRED B JR	Director	Apr 24 '25	Sale	301.82	1,712	516,716	2,998	Apr 28 04:39 PM
DAVENPORT FRED B JR	Director	Apr 24 '25	Proposed Sale	301.82	1,712	516,716		Apr 24 02:13 PM
Troendle August J.	CEO	Mar 07 '25	Option Exercise	68.62	356,446	24,458,835	1,011,102	Mar 10 05:47 PM
EWALD STEPHEN P	General Counsel & Corp. Secy.	Feb 27 '25	Buy	326.11	2	652	13,343	Feb 28 04:39 PM
Carley Brian T	Director	Feb 24 '25	Option Exercise	42.62	8,127	346,373	30,035	Feb 26 04:18 PM
Carley Brian T	Director	Feb 24 '25	Sale	345.59	4,003	1,383,397	26,032	Feb 26 04:18 PM
Carley Brian T	Director	Feb 24 '25	Proposed Sale	345.59	4,003	1,383,385		Feb 24 12:52 PM
GEIGER JESSE J	President	Dec 06 '24	Option Exercise	32.05	15,000	480,750	36,503	Dec 10 04:24 PM
BURWIG SUSAN E	Exec. VP, Operations	Nov 19 '24	Option Exercise	32.05	7,500	240,375	65,000	Nov 21 04:40 PM
Kraft Robert O.	Director	Aug 22 '24	Option Exercise	42.62	4,353	185,525	4,873	Aug 26 04:37 PM
Kraft Robert O.	Director	Aug 23 '24	Option Exercise	42.62	3,774	160,848	4,294	Aug 26 04:37 PM
Kraft Robert O.	Director	Aug 22 '24	Sale	390.73	4,353	1,700,848	520	Aug 26 04:37 PM
Kraft Robert O.	Director	Aug 23 '24	Sale	390.73	3,774	1,474,615	520	Aug 26 04:37 PM
Kraft Robert O.	Director	Aug 22 '24	Proposed Sale	390.73	4,353	1,700,858		Aug 22 04:20 PM
Keating Ashley M.	Former Director	Aug 16 '24	Proposed Sale	387.00	769	297,603		Aug 16 04:58 PM
Keating Ashley M.	Former Director	Aug 15 '24	Proposed Sale	388.00	958	371,704		Aug 15 06:27 PM
Keating Ashley M.	Former Director	Aug 09 '24	Proposed Sale	388.29	1,403	544,767		Aug 09 03:50 PM
BURWIG SUSAN E	Exec. VP, Operations	Aug 05 '24	Option Exercise	90.65	50,000	4,532,500	57,500	Aug 07 04:22 PM
Keating Ashley M.	Former Director	Aug 06 '24	Proposed Sale	382.50	2,000	765,000		Aug 06 05:27 PM
Keating Ashley M.	Former Director	Jul 30 '24	Proposed Sale	389.69	1,300	506,600		Jul 30 01:23 PM

Open in Screener

MXCT

MaxCyte Inc

Jul 25 • 04:00PM ET

2.25

Dollar change -0.02
Percentage change -0.88	%

Healthcare • Medical Devices • USA • NASD

Peers: NTLA CRSP EDIT SGMO BEAM CRBU CDXS ABCL ALLO

| Held by: VTI IWM VXF IWN IBB VTWO VHT IWC DFAS AVSC

Index	RUT	P/E	-	EPS (ttm)	-0.40	Insider Own	8.14%	Shs Outstand	106.31M	Perf Week	11.39%
Market Cap	239.22M	Forward P/E	-	EPS next Y	-0.35	Insider Trans	-0.13%	Shs Float	97.66M	Perf Month	0.90%
Enterprise Value	119.77M	PEG	-	EPS next Q	-0.10	Inst Own	70.95%	Short Float	3.56%	Perf Quarter	-20.77%
Income	-41.79M	P/S	6.35	EPS this Y	5.81%	Inst Trans	2.18%	Short Ratio	3.95	Perf Half Y	-52.73%
Sales	37.68M	P/B	1.20	EPS next Y	4.51%	ROA	-17.13%	Short Interest	3.48M	Perf YTD	-45.91%
Book/sh	1.88	P/C	1.73	EPS next 5Y	9.79%	ROE	-19.63%	52W High	5.20 -56.73%	Perf Year	-50.87%
Cash/sh	1.30	P/FCF	-	EPS past 3/5Y	-22.97% -11.37%	ROIC	-19.26%	52W Low	2.00 12.50%	Perf 3Y	-56.48%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.45% 12.31%	Gross Margin	69.93%	Volatility	5.49% 5.12%	Perf 5Y	-
Dividend TTM	-	EV/Sales	3.18	EPS Y/Y TTM	-12.34%	Oper. Margin	-133.18%	ATR (14)	0.12	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.58	Sales Y/Y TTM	-14.48%	Profit Margin	-110.92%	RSI (14)	51.94	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	12.23	EPS Q/Q	-5.79%	SMA20	2.28%	Beta	-	Target Price	6.85
Payout	-	Debt/Eq	0.09	Sales Q/Q	-8.39%	SMA50	1.25%	Rel Volume	0.38	Prev Close	2.27
Employees	114	LT Debt/Eq	0.09	Earnings	Aug 06 AMC	SMA200	-31.13%	Avg Volume	879.27K	Price	2.25
IPO	Dec 05, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-3.41% 13.44%	Trades		Volume	334,869	Change	-0.88%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-22-25	Initiated	Stephens	Overweight	$6
Nov-29-23	Initiated	Craig Hallum	Buy	$7
Oct-15-21	Resumed	Cowen	Outperform
Aug-24-21	Initiated	William Blair	Outperform
Aug-24-21	Initiated	Wedbush	Outperform	$36
Aug-24-21	Initiated	Stifel	Buy	$18
Aug-24-21	Initiated	Stephens	Overweight	$19
Aug-24-21	Initiated	Cowen	Outperform
Aug-24-21	Initiated	BTIG Research	Buy	$22

Jul-09-25 08:05AM	MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
Jul-01-25 01:00AM	PHC Announces Exclusive Distribution of MaxCyte® ExPERT Platform in Japan (Business Wire)
Jun-11-25 02:00AM	MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies (GlobeNewswire)
May-13-25 10:51AM	MaxCyte, Inc. (MXCT): A Bull Case Theory (Insider Monkey)
May-08-25 03:27AM	MaxCyte Inc (MXCT) Q1 2025 Earnings Call Highlights: Strong Revenue Alignment Amidst Growth ... (GuruFocus.com) -11.31%
06:30PM	Loading…
May-07-25 06:30PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance (GlobeNewswire)
Apr-10-25 02:00AM	MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire) -7.51%
Apr-08-25 09:35AM	Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT) (Zacks) -5.67%
Apr-07-25 09:35AM	Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround (Zacks)
Apr-04-25 12:00PM	MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know (Zacks) -5.77%
Mar-12-25 03:07AM	MaxCyte Inc (MXCT) Q4 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges (GuruFocus.com) -8.36%
Mar-11-25 04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance (GlobeNewswire)
Feb-12-25 02:00AM	MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs (GlobeNewswire)
Feb-07-25 02:00AM	MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference (GlobeNewswire)
02:00AM	Loading…
Jan-30-25 02:00AM	MaxCyte Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments (GlobeNewswire)
Jan-15-25 12:00PM	All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy (Zacks)
Jan-13-25 03:05AM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) +11.59%
Dec-23-24 02:00AM	MaxCyte Announces Retirement of Board Member Art Mandell (GlobeNewswire)
Dec-09-24 02:00AM	MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance (GlobeNewswire) +15.83%
Nov-13-24 08:05AM	MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics (GlobeNewswire)
Nov-07-24 02:00PM	MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ... (GuruFocus.com) -10.82%
Nov-06-24 05:55PM	MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance (GlobeNewswire)
Oct-31-24 08:05AM	MaxCyte to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Oct-16-24 12:00PM	MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Oct-15-24 08:05AM	MaxCyte Appoints Cynthia Collins to its Board of Directors (GlobeNewswire)
Oct-11-24 08:05AM	MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-10-24 08:05AM	MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer (GlobeNewswire)
Oct-09-24 05:08PM	MaxCyte Inc (MXCT) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Core Challenges (GuruFocus.com) -5.41%
03:32AM	Loading…
Sep-17-24 03:32AM	MaxCyte and Kamau Therapeutics sign platform license agreement (Pharmaceutical Technology)
Sep-16-24 02:00AM	MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases (GlobeNewswire)
Sep-05-24 04:05PM	MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference (GlobeNewswire)
Aug-06-24 05:50PM	MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -8.31%
04:05PM	MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance (GlobeNewswire)
Jul-17-24 08:50AM	MaxCyte (MXCT) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jul-09-24 04:05PM	MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024 (GlobeNewswire)
Jun-13-24 09:55AM	Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect? (Zacks)
08:50AM	Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why (Zacks)
Jun-11-24 01:30AM	Insider Buying: President and CEO Maher Masoud Acquires 100,000 Shares of MaxCyte Inc (MXCT) (GuruFocus.com) -5.65%
May-29-24 08:05AM	MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference (GlobeNewswire)
May-22-24 08:05AM	MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development (GlobeNewswire)
May-12-24 08:19AM	MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 02:39PM	MaxCyte Shares Rise Sharply After Q1 Results Beat (MT Newswires) +18.07%
06:35AM	Q1 2024 MaxCyte Inc Earnings Call (Thomson Reuters StreetEvents)
03:58AM	MaxCyte Inc (MXCT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ... (GuruFocus.com)
May-07-24 08:58PM	MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:45PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance (GlobeNewswire)
Apr-10-24 08:05AM	MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-02-24 08:05AM	MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs) (GlobeNewswire)
Mar-14-24 08:15AM	MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-13-24 08:17AM	11 Oversold Healthcare Stocks To Buy Right Now (Insider Monkey)
Mar-12-24 05:31PM	MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance (GlobeNewswire)
Mar-04-24 04:05PM	MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results (GlobeNewswire) -12.21%
Feb-09-24 08:05AM	MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-30-24 08:05AM	MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugens Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers (GlobeNewswire)
Jan-23-24 08:05AM	MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs (GlobeNewswire)
Jan-08-24 04:05PM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +13.73%
Jan-03-24 08:05AM	MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline (GlobeNewswire) -11.60%
Jan-02-24 02:00AM	MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director (GlobeNewswire) +6.38%
Dec-19-23 11:21AM	Hedge Funds Say These Penny Stocks Are Poised to Explode (Insider Monkey) +9.01%
Dec-11-23 04:05PM	MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023 (GlobeNewswire)
Dec-07-23 11:05AM	Insider Sell Alert: President and CEO Douglas Doerfler Sells 124,450 Shares of MaxCyte Inc (MXCT) (GuruFocus.com)
Dec-02-23 09:04AM	Insider Sell Alert: President and CEO Douglas Doerfler Sells 25,550 Shares of MaxCyte Inc (MXCT) (GuruFocus.com)
Nov-16-23 08:05AM	MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member (GlobeNewswire)
Nov-09-23 12:57PM	MaxCyte, Inc. (NASDAQ:MXCT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 04:05PM	MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance (GlobeNewswire)
Nov-06-23 04:05PM	MaxCyte to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Oct-05-23 12:59PM	Why Shares of MaxCyte Are Plummeting on Thursday (Motley Fool) -20.64%
08:47AM	Why Is MaxCyte (MXCT) Stock Down 21% Today? (InvestorPlace)
Oct-04-23 04:05PM	MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance (GlobeNewswire) +9.00%
Sep-06-23 08:05AM	MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing (GlobeNewswire)
Sep-05-23 08:05AM	MaxCyte to Participate in Baird Global Healthcare Conference (GlobeNewswire)
Aug-09-23 04:05PM	MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance (GlobeNewswire) -10.44%
Aug-01-23 08:05AM	MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients (GlobeNewswire)
Jul-13-23 08:05AM	MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023 (GlobeNewswire)
Jul-10-23 08:05AM	MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies (GlobeNewswire) +7.78%
Jul-08-23 04:54AM	MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 77% of the company (Simply Wall St.)
Jul-06-23 08:05AM	MaxCyte Signs Strategic Platform License with Lyell Immunopharma (GlobeNewswire)
Jun-01-23 04:05PM	MaxCyte to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.56%
May-30-23 08:18AM	Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth (Simply Wall St.)
May-14-23 03:11AM	Earnings Working Against MaxCyte, Inc.'s (LON:MXCT) Share Price Following 28% Dive (Simply Wall St.)
May-10-23 05:25PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -19.78%
04:05PM	MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance (GlobeNewswire)
May-04-23 08:05AM	MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform (GlobeNewswire)
Apr-28-23 05:03AM	MaxCyte, Inc. (LON:MXCT) insider upped their holding by 400% earlier this year (Simply Wall St.)
Apr-27-23 06:36PM	7 Small-Cap Biotech Stocks with Massive Potential (InvestorPlace)
Apr-12-23 04:05PM	MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023 (GlobeNewswire)
Apr-06-23 09:30AM	The three-year returns have been strong for MaxCyte (LON:MXCT) shareholders despite underlying losses increasing (Simply Wall St.)
Mar-27-23 04:05PM	MaxCyte Appoints Douglas Swirsky as Chief Financial Officer (GlobeNewswire)
Mar-18-23 02:06AM	MaxCyte, Inc. (NASDAQ:MXCT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-17-23 01:33AM	MaxCyte Full Year 2022 Earnings: US$0.23 loss per share (vs US$0.21 loss in FY 2021) (Simply Wall St.)
Mar-15-23 04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) +6.43%
Mar-08-23 08:00AM	MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology (GlobeNewswire)
Mar-06-23 04:05PM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance (PR Newswire) -7.55%
Feb-22-23 06:37PM	7 Must-Buy Penny Stocks to Add to Your Portfolio in 2023 (InvestorPlace)
Feb-01-23 04:05PM	MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-29-23 03:03AM	A fantastic week for MaxCyte, Inc.'s (LON:MXCT) 70% institutional owners, one-year returns continue to impress (Simply Wall St.)

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hemrajani Rekha	Director	Jun 25 '25	Proposed Sale	2.09	10,684	22,378		Jun 25 04:05 PM
Soleymannezhad Ali	Chief Commercial Officer	Mar 18 '25	Sale	3.18	1,211	3,850	59,439	Mar 20 06:49 PM
Sandoval David I.	GENERAL COUNSEL	Mar 18 '25	Sale	3.18	353	1,122	64,219	Mar 20 06:47 PM
Swirsky Douglas J	CHIEF FINANCIAL OFFICER	Mar 18 '25	Sale	3.18	6,939	22,061	111,811	Mar 20 06:08 PM
Johnston John Joseph	Director	Jan 27 '25	Option Exercise	2.93	3,000	8,796	144,950	Jan 29 04:13 PM
Johnston John Joseph	Director	Jan 27 '25	Sale	4.64	3,000	13,935	141,950	Jan 29 04:13 PM
Sandoval David I.	GENERAL COUNSEL	Jan 13 '25	Sale	4.54	4,466	20,272	41,447	Jan 14 04:03 PM
Johnston John Joseph	Director	Dec 26 '24	Option Exercise	2.93	3,000	8,796	144,950	Dec 30 04:15 PM
Johnston John Joseph	Director	Dec 26 '24	Sale	4.01	3,000	12,021	141,950	Dec 30 04:15 PM
Johnston John Joseph	Affiliate	Dec 26 '24	Proposed Sale	4.11	12,000	49,320		Dec 26 04:16 PM
Johnston John Joseph	Director	Dec 09 '24	Option Exercise	2.35	2,495	5,863	144,445	Dec 10 04:30 PM
Johnston John Joseph	Director	Dec 06 '24	Option Exercise	2.93	505	1,478	142,455	Dec 10 04:30 PM
Johnston John Joseph	Director	Dec 09 '24	Sale	3.79	2,495	9,459	141,950	Dec 10 04:30 PM
Johnston John Joseph	Director	Dec 06 '24	Sale	3.70	505	1,869	141,950	Dec 10 04:30 PM
Erck Stanley C	Director	Nov 01 '24	Option Exercise	0.04	47,689	1,908	316,807	Nov 05 04:25 PM
Erck Stanley C	Director	Nov 01 '24	Sale	3.72	47,689	177,403	269,118	Nov 05 04:25 PM
Johnston John Joseph	Director	Oct 28 '24	Option Exercise	2.93	3,000	8,778	144,950	Oct 30 04:15 PM
Johnston John Joseph	Director	Oct 28 '24	Sale	3.72	3,000	11,166	141,950	Oct 30 04:15 PM
Erck Stanley C	Director	Oct 01 '24	Option Exercise	0.04	26,082	1,043	295,200	Oct 02 05:03 PM
Erck Stanley C	Director	Oct 02 '24	Option Exercise	0.04	21,607	864	290,725	Oct 02 05:03 PM
Erck Stanley C	Director	Oct 01 '24	Sale	3.78	26,082	98,590	269,118	Oct 02 05:03 PM
Erck Stanley C	Director	Oct 02 '24	Sale	3.71	21,607	80,162	269,118	Oct 02 05:03 PM
Johnston John Joseph	Director	Sep 26 '24	Option Exercise	2.93	3,000	8,778	144,950	Sep 30 04:15 PM
Johnston John Joseph	Director	Sep 26 '24	Sale	3.82	3,000	11,460	141,950	Sep 30 04:15 PM
Johnston John Joseph	Affiliate	Sep 26 '24	Proposed Sale	3.81	9,000	34,290		Sep 26 04:11 PM
Erck Stanley C	Director	Sep 04 '24	Option Exercise	0.04	29,767	1,191	298,885	Sep 05 05:10 PM
Erck Stanley C	Director	Sep 03 '24	Option Exercise	0.04	17,922	717	287,040	Sep 05 05:10 PM
Erck Stanley C	Director	Sep 04 '24	Sale	3.97	29,767	118,175	269,118	Sep 05 05:10 PM
Erck Stanley C	Director	Sep 03 '24	Sale	4.10	17,922	73,480	269,118	Sep 05 05:10 PM
Erck Stanley C	Officer	Sep 03 '24	Proposed Sale	4.32	143,067	618,049		Sep 03 04:36 PM
Johnston John Joseph	Director	Aug 26 '24	Option Exercise	2.93	3,000	8,778	144,950	Aug 28 04:30 PM
Johnston John Joseph	Director	Aug 26 '24	Sale	4.28	3,000	12,840	141,950	Aug 28 04:30 PM
Ross Thomas M.	EVP, GLOBAL SALES	Aug 02 '24	Option Exercise	1.64	17,857	29,303	42,857	Aug 05 06:57 PM
Ross Thomas M.	EVP, GLOBAL SALES	Aug 01 '24	Option Exercise	1.64	15,476	25,396	40,476	Aug 05 06:57 PM
Ross Thomas M.	EVP, GLOBAL SALES	Aug 02 '24	Sale	4.36	17,857	77,874	25,000	Aug 05 06:57 PM
Ross Thomas M.	EVP, GLOBAL SALES	Aug 01 '24	Sale	4.54	15,476	70,261	25,000	Aug 05 06:57 PM

IQV IQVIA Holdings Inc daily Stock Chart

Peers: CROX MEDP LH ICON CTLT CRL INCY

| Held by: VTI VOO VO SPY IVV VTV XLV IBB COWZ RSP

Index	S&P 500	P/E	28.85	EPS (ttm)	6.90	Insider Own	0.87%	Shs Outstand	170.00M	Perf Week	23.99%
Market Cap	33.86B	Forward P/E	15.44	EPS next Y	12.90	Insider Trans	-0.34%	Shs Float	168.53M	Perf Month	25.49%
Enterprise Value	47.38B	PEG	3.39	EPS next Q	2.98	Inst Own	96.75%	Short Float	5.37%	Perf Quarter	32.18%
Income	1.24B	P/S	2.16	EPS this Y	6.64%	Inst Trans	-3.31%	Short Ratio	3.67	Perf Half Y	-3.32%
Sales	15.70B	P/B	5.86	EPS next Y	8.65%	ROA	4.50%	Short Interest	9.05M	Perf YTD	1.35%
Book/sh	33.99	P/C	15.47	EPS next 5Y	8.50%	ROE	19.80%	52W High	252.88 -21.24%	Perf Year	-16.59%
Cash/sh	12.87	P/FCF	16.85	EPS past 3/5Y	14.76% 50.90%	ROIC	6.13%	52W Low	134.65 47.92%	Perf 3Y	-9.71%
Dividend Est.	-	EV/EBITDA	14.01	Sales past 3/5Y	3.54% 6.79%	Gross Margin	27.09%	Volatility	5.30% 3.60%	Perf 5Y	28.33%
Dividend TTM	-	EV/Sales	3.02	EPS Y/Y TTM	-10.72%	Oper. Margin	14.40%	ATR (14)	7.05	Perf 10Y	159.13%
Dividend Ex-Date	-	Quick Ratio	0.84	Sales Y/Y TTM	3.53%	Profit Margin	7.88%	RSI (14)	77.60	Recom	1.54
Dividend Gr. 3/5Y	- -	Current Ratio	0.84	EPS Q/Q	-22.02%	SMA20	18.39%	Beta	1.31	Target Price	211.74
Payout	0.00%	Debt/Eq	2.72	Sales Q/Q	5.27%	SMA50	27.30%	Rel Volume	0.87	Prev Close	200.82
Employees	88000	LT Debt/Eq	2.49	Earnings	Jul 22 BMO	SMA200	8.84%	Avg Volume	2.47M	Price	199.17
IPO	May 09, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.42% 1.19%	Trades		Volume	2,138,894	Change	-0.82%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-25-25	Downgrade	HSBC Securities	Buy → Hold	$160
Apr-10-25	Downgrade	Barclays	Overweight → Equal Weight	$170
Feb-03-25	Downgrade	BTIG Research	Buy → Neutral
Dec-20-24	Initiated	Stephens	Overweight	$250
Oct-14-24	Initiated	Redburn Atlantic	Buy
Sep-04-24	Initiated	RBC Capital Mkts	Outperform	$275
Jul-24-24	Downgrade	Jefferies	Buy → Hold	$266 → $242
Jun-06-24	Initiated	Goldman	Buy	$270
Feb-26-24	Initiated	Leerink Partners	Outperform	$290
Feb-15-24	Downgrade	Guggenheim	Buy → Neutral
Feb-13-24	Initiated	BTIG Research	Buy	$285
Nov-02-23	Downgrade	Robert W. Baird	Outperform → Neutral	$248 → $202
Sep-06-23	Initiated	HSBC Securities	Buy	$260
Mar-17-23	Initiated	Truist	Buy	$265
Dec-06-22	Initiated	Cowen	Outperform	$251
Nov-17-22	Downgrade	Citigroup	Buy → Neutral	$275 → $245
Aug-25-22	Initiated	Credit Suisse	Outperform	$300
Jul-15-22	Initiated	SVB Leerink	Outperform	$256
May-24-22	Initiated	Guggenheim	Buy	$244
Apr-29-22	Upgrade	Piper Sandler	Neutral → Overweight	$231 → $255

Show Previous Ratings

Jul-24-25 06:37PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
11:17AM	Veeva's Vault Vision: Can It Thrive After Parting With Salesforce? (Zacks)
Jul-23-25 02:23PM	IQVIA Holdings (IQV) Snaps 2-Day Losses on Higher-than-Expected Earnings (Insider Monkey)
01:31PM	Why IQVIA (IQV) Stock Is Up Today (StockStory)
09:58AM	Fiserv's Q2 Earnings Surpass Estimates, Revenues Increase Y/Y (Zacks)
08:37AM	Loading…
08:37AM	Stock Market News for Jul 23, 2025 (Zacks)
03:08AM	IQVIA Holdings Inc (IQV) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic AI ... (GuruFocus.com)
01:32AM	IQV Q2 Deep Dive: AI Initiatives and Pipeline Growth Drive Outperformance Amid Margin Pressures (StockStory)
Jul-22-25 05:55PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research) +17.88%
04:38PM	S&P 500 Gains & Losses Today: Homebuilder Stocks Soar; Lockheed Martin Loses Altitude (Investopedia)
04:06PM	Medpace Surges 55% On 'Shockingly Strong' Report; Pulling Iqvia Higher (Investor's Business Daily)
02:53PM	IQVIA Leads S&P 500 Gainers on Better-Than-Expected Earnings (Investopedia)
12:23PM	Top Stock Movers Now: GM, Lockheed Martin, IQVIA, DR Horton, and More (Investopedia)
12:15PM	IQVIA Earnings & Revenues Beat Estimates in Q2, Rise Y/Y (Zacks)
11:55AM	Why IQVIA (IQV) Stock Is Trading Up Today (StockStory)
09:08AM	Loading…
09:08AM	Iqvia Surges As 'Pluses' Outweigh 'Minuses' In Its Second-Quarter Report (Investor's Business Daily)
08:15AM	IQVIA Holdings (IQV) Q2 Earnings and Revenues Surpass Estimates (Zacks)
07:37AM	IQVIA (NYSE:IQV) Beats Q2 Sales Targets, Stock Soars (StockStory)
07:16AM	IQVIA: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	IQVIA Reports Second-Quarter 2025 Results (Business Wire)
Jul-20-25 11:02PM	IQVIA Earnings: What To Look For From IQV (StockStory)
Jul-17-25 09:15AM	Countdown to IQVIA (IQV) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
08:52AM	What Makes IQVIA Holdings (IQV) an Investment Bet? (Insider Monkey)
08:08AM	Is IQVIA Holdings (IQV) an Attractive Investment Opportunity? (Insider Monkey)
Jul-16-25 10:00AM	Analysts Estimate Thermo Fisher Scientific (TMO) to Report a Decline in Earnings: What to Look Out for (Zacks)
09:42AM	IQVIA Gears Up to Report Q2 Earnings: What's in Store for the Stock? (Zacks)
Jul-15-25 05:06PM	Top Stock Reports for Amazon.com, Meta Platforms & Shopify (Zacks)
10:00AM	IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy? (Zacks)
12:05AM	3 Reasons IQV is Risky and 1 Stock to Buy Instead (StockStory)
Jul-11-25 09:45AM	Why IQVIA Holdings (IQV) is a Top Growth Stock for the Long-Term (Zacks)
11:40AM	Loading…
Jul-10-25 11:40AM	IQVIA Unveils New Custom AI Agents with NVIDIA (Insider Monkey)
09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
Jul-09-25 11:52AM	Veeva Expands Market Reach Through Targeted Strategic Partnerships (Zacks)
Jul-08-25 12:05PM	VEEV Rises 29% in 3 Months: Should You Buy the Stock Now or Wait? (Zacks)
09:34AM	Healthcare's $110B AI Surge Is Picking Up Speed--and It's Just the Beginning (PR Newswire)
05:08AM	What to Expect From IQVIA Holdings' Q2 2025 Earnings Report (Barchart)
Jul-02-25 10:05AM	VEEV Integrates GenAI in Vault Platform to Drive Workflow Automation (Zacks)
Jul-01-25 07:00AM	IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025 (Business Wire)
Jun-30-25 12:39AM	3 Healthcare Stocks Skating on Thin Ice (StockStory)
Jun-27-25 09:15AM	Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last? (Zacks)
Jun-26-25 06:01PM	The Top 5 Analyst Questions From IQVIA's Q1 Earnings Call (StockStory)
10:15AM	Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect. (Investor's Business Daily)
Jun-17-25 10:18AM	AI Healthcare Funding Surges as Real-World Rollouts Hit Pharmacies, Hospitals, and Providers (PR Newswire)
Jun-16-25 11:34PM	Drug Development Inputs & Services Stocks Q1 Highlights: IQVIA (NYSE:IQV) (StockStory)
09:00AM	IQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for 'Best Mobile App for Patient Engagement' (Business Wire)
Jun-11-25 07:00AM	IQVIA Launches New AI Agents for Life Sciences and Healthcare (Business Wire)
Jun-05-25 11:44AM	Doximity Declines 4.4% in a Month: How to Play the Stock Now? (Zacks)
Jun-02-25 04:37PM	IQVIA Announces Pricing of Senior Notes (Business Wire)
08:10AM	IQVIA Announces Offering of Senior Notes (Business Wire)
May-31-25 03:00AM	Ipca Laboratories Ltd (BOM:524494) Q4 2025 Earnings Call Highlights: Strong Domestic Growth and ... (GuruFocus.com)
May-27-25 07:00AM	Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF (PR Newswire)
May-19-25 08:48AM	IQV Q1 Earnings Call: Real-World Evidence Drives Outperformance Amid Sector Uncertainty (StockStory)
05:40AM	IQVIA and SCRI partner to enhance oncology trials (Clinical Trials Arena)
May-16-25 08:00AM	IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials (Business Wire)
May-14-25 04:54PM	S&P 500 Gains & Losses Today: Supermicro Stock Surges After DataVolt Deal (Investopedia) -5.88%
May-13-25 09:16AM	Investing in IQVIA (IQV)? Don't Miss Assessing Its International Revenue Trends (Zacks)
May-07-25 06:03PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
04:15PM	IQVIA CFO Ron Bruehlman to speak at the Bank of America Annual Health Care Conference on May 13 (Business Wire)
03:12AM	IQVIA Holdings Inc (IQV) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
02:44AM	Q1 2025 IQVIA Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
May-06-25 09:00PM	IQVIA (IQV) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
12:33PM	IQVIA Earnings & Revenues Beat Estimates in Q1, Increase Y/Y (Zacks)
08:10AM	IQVIA Holdings (IQV) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
07:10AM	IQVIA: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	IQVIA Reports First-Quarter 2025 Results (Business Wire)
May-05-25 03:05AM	After an up and down year, pharmas R&D landscape is shifting again (Pharma Voice)
May-01-25 09:34AM	IQVIA Gears Up to Report Q1 Earnings: What's in Store for the Stock? (Zacks)
09:15AM	IQVIA (IQV) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures (Zacks)
Apr-30-25 10:01AM	RxSight, Inc. (RXST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-29-25 10:01AM	IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-28-25 06:50PM	IQVIA Holdings Inc. (IQV): Among Billionaire Israel Englander's Stock Picks with Huge Upside Potential (Insider Monkey)
09:00AM	IQVIA celebrates Marie E. Lamont and Dr. Joanne Hackett, winners of Healthcare Businesswomen's Association Awards (Business Wire)
Apr-27-25 11:40PM	Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results (Seeking Alpha)
Apr-25-25 09:18AM	HSBC shuffles MedTech stocks, cutting 4, upgrading 2 (Investing.com)
09:16AM	3 Healthcare Stocks That Concern Us (StockStory)
Apr-23-25 09:00AM	IQVIA named a front-runner in generative AI innovation by global industry research and analysis firm (Business Wire)
02:38AM	Oakmark U.S. Concentrated Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-21-25 04:15PM	IQVIA to Announce First-Quarter 2025 Results on May 6, 2025 (Business Wire)
Apr-16-25 02:41PM	IYH: Healthcare Dashboard For April (Seeking Alpha)
12:30AM	Cedar Creek Partners Q1 2025 Results (Seeking Alpha)
Apr-15-25 08:00AM	Stabilization and improvement seen in multiple key biopharma R&D metrics, says IQVIA Institute Report (Business Wire)
Apr-11-25 12:30PM	Oakmark Global Select Fund Q1 2025 Commentary (Seeking Alpha)
12:20PM	Oakmark Select Fund Q1 2025 Commentary (Seeking Alpha)
Apr-10-25 10:42AM	IQVIA (IQV) Moves 8.7% Higher: Will This Strength Last? (Zacks) -8.79%
Apr-08-25 09:43AM	IQVIA Holdings Inc. (IQV): Among Stocks with Buy Ratings that Hedge Funds Love (Insider Monkey) -5.57%
Apr-01-25 02:27AM	Impax Global Social Leaders Fund Q4 2024 Commentary (Seeking Alpha)
Mar-31-25 03:15PM	Impax Large Cap Fund Q4 2024 Commentary (Seeking Alpha)
Mar-27-25 06:32PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
Mar-26-25 10:59AM	Paychex Q3 Earnings & Revenues Surpass Estimates, Increase Y/Y (Zacks)
10:53AM	Here's Why Investors Must Hold IQV Stock in Their Portfolios Now (Zacks)
05:03AM	Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks (StockStory)
Mar-24-25 12:35PM	Why IQVIA Holdings Inc. (IQV) is Among the Best Diagnostics Stocks to Invest in Right Now (InsiderMonkey)
Mar-23-25 08:06PM	Tracking William Nygren's Harris Associates Portfolio - Q4 2024 Update (SeekingAlpha)
Mar-21-25 07:40AM	IQVIA Holdings (IQV) Fell on Lowered Guidance (InsiderMonkey)
Mar-20-25 02:50AM	Lazard Global Equity Select Portfolio Q4 2024 Commentary (SeekingAlpha)
Mar-19-25 05:09AM	3 Reasons IQV is Risky and 1 Stock to Buy Instead (StockStory)
Mar-10-25 09:00AM	IQVIA recognized as a leader in IDC MarketScapes 2024 assessment for decentralized clinical trial technologies and consulting services (Business Wire)
Mar-04-25 09:00AM	IQVIA Laboratories launches Site Lab Navigator with breakthrough e-Requisition innovation to transform clinical trials (Business Wire)
Feb-25-25 09:40AM	IQVIA Holdings (IQV) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Feb-24-25 09:00AM	IQVIA AI Assistant wins 2024 PM360 Innovation Award for Artificial Intelligence (Business Wire)

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cherofsky Keriann	See Remarks	Jul 23 '25	Sale	191.53	549	105,150	2,910	Jul 25 05:01 PM
Sherbet Eric	See Remarks	Jul 23 '25	Option Exercise	97.20	11,870	1,153,764	32,978	Jul 25 05:00 PM
Sherbet Eric	See Remarks	Jul 23 '25	Sale	190.05	5,800	1,102,290	27,178	Jul 25 05:00 PM
ERIC SHERBET	Officer	Jul 23 '25	Proposed Sale	190.05	5,800	1,102,262		Jul 23 05:53 PM
KERIANN CHEROFSKY	Officer	Jul 23 '25	Proposed Sale	191.53	549	105,150		Jul 23 04:01 PM
BOUSBIB ARI	See Remarks	Feb 10 '25	Option Exercise	65.16	40,000	2,606,400	837,083	Feb 12 05:11 PM
DANHAKL JOHN G	Director	Dec 03 '24	Buy	200.58	1,275	255,740	1,275	Feb 07 07:03 PM
Sherbet Eric	See Remarks	Aug 27 '24	Sale	246.33	1,300	320,229	19,536	Aug 29 05:02 PM
Sherbet Eric	Officer	Aug 27 '24	Proposed Sale	246.33	1,300	320,229		Aug 27 05:23 PM

INCY

NOTV

CRL

OABI

NRC

MEDP

MXCT

IQV

Upgrade your FINVIZ experience